<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1209211036
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ceftriaxone Venus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTRIAXONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VENUS REMEDIES LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VENUS REMEDIES LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            VENUS REMEDIES LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ceftriaxone Venus is an antibiotic given to adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.</p><p>Ceftriaxone Venus is used to treat infections of</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the brain (meningitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the middle ear.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the abdomen and abdominal wall (peritonitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the urinary tract and kidneys.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bones and joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the skin or soft tissues.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the heart.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It can be given:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat specific sexually transmitted infections (gonorrhoea and syphilis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat patients with low white blood cell counts (neutropenia) who have fever due to bacterial infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat infections of the chest in adults with chronic bronchitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat Lyme disease (caused by tick bites) in adults and children including newborn babies from 15 days of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent infections during surgery.</p><p>&nbsp;</p><p>Ceftriaxone Venus is an antibiotic given to adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.</p><p>Ceftriaxone Venus is used to treat infections of</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the brain (meningitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the middle ear.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the abdomen and abdominal wall (peritonitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the urinary tract and kidneys.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bones and joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the skin or soft tissues.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the heart.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It can be given:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat specific sexually transmitted infections (gonorrhoea and syphilis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat patients with low white blood cell counts (neutropenia) who have fever due to bacterial infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat infections of the chest in adults with chronic bronchitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat Lyme disease (caused by tick bites) in adults and children including newborn babies from 15 days of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent infections during surgery.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Ceftriaxone Venus if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to Ceftriaxone Venus or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had a sudden or severe allergic reaction to penicillin or similar antibiotics (such as cephalosporins, carbapenems or monobactams). The signs include sudden swelling of the throat or face which might make it difficult to breath or swallow, sudden swelling of the hands, feet and ankles, and a severe rash that develops quickly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to lidocaine and you are to be given Ceftriaxone Venus as an injection into a muscle.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; Ceftriaxone Venus must not be given to babies if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The baby is premature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The baby is newborn (up to 28 days of age) and has certain blood problems or jaundice (yellowing of the skin or the whites of the eyes) or is to be given a product that contains calcium into their vein.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before you are given Ceftriaxone Venus if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have recently received or are about to receive products that contain calcium.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have recently had diarrhoea after having an antibiotic medicine. You have ever had problems with your gut, in particular colitis (inflammation of the bowel).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver or kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have gall stones or kidney stones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have other illnesses, such as haemolytic anaemia (a reduction in your red blood cells that may make your skin pale yellow and cause weakness or breathlessness).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are on a low sodium diet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You experience or have previously experienced a combination of any of the following symptoms: rash, red skin, blistering of the lips eyes and mouth, skin peeling, high fever, flu-like symptoms, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (signs of severe skin reactions, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>&nbsp;</p><p><strong>If you need a blood or urine test</strong></p><p>If you are given Ceftriaxone Venus for a long time, you may need to have regular blood tests. Ceftriaxone Venus can affect the results of urine tests for sugar and a blood test known as the Coombs test. If you are having tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell the person taking the sample that you have been given Ceftriaxone Venus.</p><p>If you are diabetic or need to have your blood glucose level monitored you should not use certain blood glucose monitoring systems which may estimate blood glucose incorrectly while you are receiving Ceftriaxone Venus. If you use such systems check the instructions for use and tell your doctor, pharmacist or nurse. Alternative testing methods should be used if necessary.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>Talk to your doctor or pharmacist or nurse before your child is administered Ceftriaxone Venus if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He/She has recently been given or is to be given a product that contains calcium into their vein.</p><p>&nbsp;</p><p><strong>Other medicines and Ceftriaxone Venus</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A type of antibiotic called an aminoglycoside.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes).</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>The doctor will consider the benefit of treating you with Ceftriaxone Venus against the risk to your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Ceftriaxone Venus can cause dizziness. If you feel dizzy, do not drive or use any tools or machines. Talk to your doctor if you experience these symptoms.</p><p>&nbsp;</p><p><strong>Sodium:</strong></p><p>This medicine contains 82.8 mg (1 g vial) of sodium per dose. This is equivalent to 4.14-8.28% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p><strong>You must not be given Ceftriaxone Venus if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to Ceftriaxone Venus or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had a sudden or severe allergic reaction to penicillin or similar antibiotics (such as cephalosporins, carbapenems or monobactams). The signs include sudden swelling of the throat or face which might make it difficult to breath or swallow, sudden swelling of the hands, feet and ankles, and a severe rash that develops quickly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to lidocaine and you are to be given Ceftriaxone Venus as an injection into a muscle.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; Ceftriaxone Venus must not be given to babies if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The baby is premature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The baby is newborn (up to 28 days of age) and has certain blood problems or jaundice (yellowing of the skin or the whites of the eyes) or is to be given a product that contains calcium into their vein.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before you are given Ceftriaxone Venus if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have recently received or are about to receive products that contain calcium.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have recently had diarrhoea after having an antibiotic medicine. You have ever had problems with your gut, in particular colitis (inflammation of the bowel).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver or kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have gall stones or kidney stones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have other illnesses, such as haemolytic anaemia (a reduction in your red blood cells that may make your skin pale yellow and cause weakness or breathlessness).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are on a low sodium diet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You experience or have previously experienced a combination of any of the following symptoms: rash, red skin, blistering of the lips eyes and mouth, skin peeling, high fever, flu-like symptoms, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (signs of severe skin reactions, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>&nbsp;</p><p><strong>If you need a blood or urine test</strong></p><p>If you are given Ceftriaxone Venus for a long time, you may need to have regular blood tests. Ceftriaxone Venus can affect the results of urine tests for sugar and a blood test known as the Coombs test. If you are having tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell the person taking the sample that you have been given Ceftriaxone Venus.</p><p>If you are diabetic or need to have your blood glucose level monitored you should not use certain blood glucose monitoring systems which may estimate blood glucose incorrectly while you are receiving Ceftriaxone Venus. If you use such systems check the instructions for use and tell your doctor, pharmacist or nurse. Alternative testing methods should be used if necessary.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>Talk to your doctor or pharmacist or nurse before your child is administered Ceftriaxone Venus if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He/She has recently been given or is to be given a product that contains calcium into their vein.</p><p>&nbsp;</p><p><strong>Other medicines and Ceftriaxone Venus</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A type of antibiotic called an aminoglycoside.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes).</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>The doctor will consider the benefit of treating you with Ceftriaxone Venus against the risk to your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Ceftriaxone Venus can cause dizziness. If you feel dizzy, do not drive or use any tools or machines. Talk to your doctor if you experience these symptoms.</p><p>&nbsp;</p><p><strong>Sodium:</strong></p><p>This medicine contains 82.8 mg (1 g vial) of sodium per dose. This is equivalent to 4.14-8.28% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ceftriaxone Venus is usually given by a doctor or nurse. It can be given as&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a drip (intravenous infusion) or as an injection directly into a vein or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; into a muscle.</p><p>Ceftriaxone Venus is made up by the doctor, pharmacist or nurse and will not be mixed with or given to you at the same time as calcium-containing injections.</p><p>&nbsp;</p><p><strong>The usual dose</strong></p><p>Your doctor will decide the correct dose of Ceftriaxone Venus for you. The dose will depend on the severity and type of infection; whether you are on any other antibiotics; your weight and age; how well your kidneys and liver are working. The number of days or weeks that you are given Ceftriaxone Venus depends on what sort of infection you have.</p><p><strong>&nbsp;</strong></p><p>Adults, older people and children aged 12 years and over with a body weight greater than or equal to 50 kilograms (kg):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 to 2 g once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose (up to 4 g once a day). If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p><strong>&nbsp;</strong></p><p>Newborn babies, infants and children aged 15 days to 12 years with a body weight of less than 50 kg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50-80 mg Ceftriaxone Venus for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose up to 100 mg for each kg of body weight to a maximum of 4 g once a day. If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with a body weight of 50 kg or more should be given the usual adult dose.</p><p><strong>&nbsp;</strong></p><p>Newborn babies (0-14 days)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 &ndash; 50 mg Ceftriaxone Venus for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximum daily dose is not to be more than 50 mg for each kg of the baby&rsquo;s weight.</p><p>&nbsp;</p><p>People with liver and kidney problems</p><p>You may be given a different dose to the usual dose. Your doctor will decide how much Ceftriaxone Venus you will need and will check you closely depending on the severity of the liver and kidney disease.</p><p>&nbsp;</p><p><strong>If you are given more Ceftriaxone Venus than you should</strong></p><p>If you accidentally receive more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p>&nbsp;</p><p><strong>If you forget to use Ceftriaxone Venus</strong></p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not take a double dose (two injections at the same time) to make up for a missed dose.</p><p>&nbsp;</p><p><strong>If you stop using Ceftriaxone Venus</strong></p><p>Do not stop taking Ceftriaxone Venus unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Ceftriaxone Venus is usually given by a doctor or nurse. It can be given as&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a drip (intravenous infusion) or as an injection directly into a vein or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; into a muscle.</p><p>Ceftriaxone Venus is made up by the doctor, pharmacist or nurse and will not be mixed with or given to you at the same time as calcium-containing injections.</p><p>&nbsp;</p><p><strong>The usual dose</strong></p><p>Your doctor will decide the correct dose of Ceftriaxone Venus for you. The dose will depend on the severity and type of infection; whether you are on any other antibiotics; your weight and age; how well your kidneys and liver are working. The number of days or weeks that you are given Ceftriaxone Venus depends on what sort of infection you have.</p><p><strong>&nbsp;</strong></p><p>Adults, older people and children aged 12 years and over with a body weight greater than or equal to 50 kilograms (kg):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 to 2 g once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose (up to 4 g once a day). If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p><strong>&nbsp;</strong></p><p>Newborn babies, infants and children aged 15 days to 12 years with a body weight of less than 50 kg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50-80 mg Ceftriaxone Venus for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose up to 100 mg for each kg of body weight to a maximum of 4 g once a day. If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with a body weight of 50 kg or more should be given the usual adult dose.</p><p><strong>&nbsp;</strong></p><p>Newborn babies (0-14 days)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 &ndash; 50 mg Ceftriaxone Venus for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximum daily dose is not to be more than 50 mg for each kg of the baby&rsquo;s weight.</p><p>&nbsp;</p><p>People with liver and kidney problems</p><p>You may be given a different dose to the usual dose. Your doctor will decide how much Ceftriaxone Venus you will need and will check you closely depending on the severity of the liver and kidney disease.</p><p>&nbsp;</p><p><strong>If you are given more Ceftriaxone Venus than you should</strong></p><p>If you accidentally receive more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p>&nbsp;</p><p><strong>If you forget to use Ceftriaxone Venus</strong></p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not take a double dose (two injections at the same time) to make up for a missed dose.</p><p>&nbsp;</p><p><strong>If you stop using Ceftriaxone Venus</strong></p><p>Do not stop taking Ceftriaxone Venus unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Severe allergic reactions (not known, frequency cannot be estimated from the available data)</strong></p><p>If you have a severe allergic reaction, tell a doctor straight away.</p><p>The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of the face, throat, lips or mouth. This can make it difficult to breathe or swallow.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of the hands, feet and ankles.</p><p>&nbsp;</p><p><strong>Severe skin reactions (not known, frequency cannot be estimated from the available data)</strong></p><p>If you get a severe skin reaction, tell a doctor straight away.</p><p>The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe rash that develops quickly, with blisters or peeling of the skin and possibly blisters in the mouth (Stevens-Johnson syndrome and toxic epidermal necrolysis which are also known as SJS and TEN).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A combination of any of the following symptoms: widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jarisch-Herxheimer reaction which causes fever, chills, headache, muscle pain, and skin rash that is usually self-limiting. This occurs shortly after starting Ceftriaxone Venus treatment for infections with spirochete such as Lyme disease.</p><p>&nbsp;</p><p>Other possible side effects:</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities with your white blood cells (such as a decrease of leucocytes and an increase of eosinophils) and platelets (decrease of thrombocytes).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loose stools or diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the results of blood tests for liver functions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections (for example, thrush).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A decrease in the number of white blood cells (granulocytopenia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in number of red blood cells (anaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with the way your blood clots. The signs may include bruising easily and pain and swelling of your joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick or being sick.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritis (itching).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or a burning feeling along the vein where Ceftriaxone Venus has been given. Pain where the injection was given.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A high temperature (fever).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal kidney function test (blood creatinine increased).</p><p><strong>&nbsp;</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the large bowel (colon). The signs include diarrhoea, usually with blood and mucus, stomach pain and fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing (bronchospasm).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A lumpy rash (hives) that may cover a lot of your body, feeling itchy and swelling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood or sugar in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (fluid build-up).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering.</p><p><strong>&nbsp;</strong></p><p><strong>Not known (Frequency cannot be estimated from the available data)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A secondary infection that may not respond to the antibiotic previously prescribed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form of anaemia where red blood cells are destroyed (haemolytic anaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe decrease in white blood cells (agranulocytosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo (spinning sensation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas (pancreatitis). The signs include severe pain in the stomach which spreads to your back.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mucus lining of the mouth (stomatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tongue (glossitis). The signs include swelling, redness and soreness of the tongue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with your gallbladder, which may cause pain, feeling sick and being sick.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A neurological condition that may occur in neonates with severe jaundice (kernicterus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems caused by deposits of calcium Ceftriaxone Venus. There may be pain when passing water (urine) or low output of urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A false positive result in a Coombs&rsquo; test (a test for some blood problems).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A false positive result for galactosaemia (an abnormal build up of the sugar galactose).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ceftriaxone Venus may interfere with some types of blood glucose tests - please check with your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Severe allergic reactions (not known, frequency cannot be estimated from the available data)</strong></p><p>If you have a severe allergic reaction, tell a doctor straight away.</p><p>The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of the face, throat, lips or mouth. This can make it difficult to breathe or swallow.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of the hands, feet and ankles.</p><p>&nbsp;</p><p><strong>Severe skin reactions (not known, frequency cannot be estimated from the available data)</strong></p><p>If you get a severe skin reaction, tell a doctor straight away.</p><p>The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe rash that develops quickly, with blisters or peeling of the skin and possibly blisters in the mouth (Stevens-Johnson syndrome and toxic epidermal necrolysis which are also known as SJS and TEN).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A combination of any of the following symptoms: widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jarisch-Herxheimer reaction which causes fever, chills, headache, muscle pain, and skin rash that is usually self-limiting. This occurs shortly after starting Ceftriaxone Venus treatment for infections with spirochete such as Lyme disease.</p><p>&nbsp;</p><p>Other possible side effects:</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities with your white blood cells (such as a decrease of leucocytes and an increase of eosinophils) and platelets (decrease of thrombocytes).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loose stools or diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the results of blood tests for liver functions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections (for example, thrush).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A decrease in the number of white blood cells (granulocytopenia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in number of red blood cells (anaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with the way your blood clots. The signs may include bruising easily and pain and swelling of your joints.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick or being sick.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritis (itching).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or a burning feeling along the vein where Ceftriaxone Venus has been given. Pain where the injection was given.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A high temperature (fever).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal kidney function test (blood creatinine increased).</p><p><strong>&nbsp;</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the large bowel (colon). The signs include diarrhoea, usually with blood and mucus, stomach pain and fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing (bronchospasm).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A lumpy rash (hives) that may cover a lot of your body, feeling itchy and swelling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood or sugar in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (fluid build-up).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering.</p><p><strong>&nbsp;</strong></p><p><strong>Not known (Frequency cannot be estimated from the available data)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A secondary infection that may not respond to the antibiotic previously prescribed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form of anaemia where red blood cells are destroyed (haemolytic anaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe decrease in white blood cells (agranulocytosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo (spinning sensation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas (pancreatitis). The signs include severe pain in the stomach which spreads to your back.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mucus lining of the mouth (stomatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tongue (glossitis). The signs include swelling, redness and soreness of the tongue.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with your gallbladder, which may cause pain, feeling sick and being sick.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A neurological condition that may occur in neonates with severe jaundice (kernicterus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems caused by deposits of calcium Ceftriaxone Venus. There may be pain when passing water (urine) or low output of urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A false positive result in a Coombs&rsquo; test (a test for some blood problems).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A false positive result for galactosaemia (an abnormal build up of the sugar galactose).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ceftriaxone Venus may interfere with some types of blood glucose tests - please check with your doctor.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>- Toll free phone: 8002490000</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Council</strong><strong> of Arab Health Ministers</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>This is a Medicament</strong></p><p>1. Medicament &nbsp;is &nbsp;a &nbsp;product &nbsp;which &nbsp;affects &nbsp;your &nbsp;health &nbsp;and &nbsp;its &nbsp;consumption&nbsp; contrary &nbsp;to instructions is dangerous for you.</p><p>2. Follow strictly the doctor&#39;s prescription,&nbsp; the method of use and&nbsp; the instructions&nbsp;&nbsp; of the pharmacist who sold the medicament.</p><p>3. The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>4. Do not by yourself interrupt the period of treatment prescribed for you.</p><p>5. Do not repeat the same prescription without consulting your doctor.</p><p>6. Keep all medicaments out of reach of children.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Council of Arab Health Ministers</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Union of Arab Pharmacists</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s): </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>- Toll free phone: 8002490000</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Council</strong><strong> of Arab Health Ministers</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>This is a Medicament</strong></p><p>1. Medicament &nbsp;is &nbsp;a &nbsp;product &nbsp;which &nbsp;affects &nbsp;your &nbsp;health &nbsp;and &nbsp;its &nbsp;consumption&nbsp; contrary &nbsp;to instructions is dangerous for you.</p><p>2. Follow strictly the doctor&#39;s prescription,&nbsp; the method of use and&nbsp; the instructions&nbsp;&nbsp; of the pharmacist who sold the medicament.</p><p>3. The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>4. Do not by yourself interrupt the period of treatment prescribed for you.</p><p>5. Do not repeat the same prescription without consulting your doctor.</p><p>6. Keep all medicaments out of reach of children.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Council of Arab Health Ministers</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Union of Arab Pharmacists</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the vial or bottle label after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30<sup>o</sup>C.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Chemical and physical in-use stability of the reconstituted product has been demonstrated for at least 6 hours at or below 25&deg;C or 24 hours at 2-8&deg;C.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 to 8&deg;C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist to throw away medicines you no longer use. These measures will help protect the environment.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the vial or bottle label after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30<sup>o</sup>C.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Chemical and physical in-use stability of the reconstituted product has been demonstrated for at least 6 hours at or below 25&deg;C or 24 hours at 2-8&deg;C.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 to 8&deg;C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Ceftriaxone Venus contains</strong></p><p>Ceftriaxone Venus 1 g Powder for Solution for Injection or Infusion:</p><p>The active substance is ceftriaxone.</p><p>Each vial contains Ceftriaxone Sodium equivalent to Ceftriaxone 1 g</p><p>Each 1 gram of ceftriaxone sodium contains approximately 3.6 mmol (82.8 mg) sodium.</p><p>The vial contains no other ingredients.</p><p>The displacement volume of 1 g of Ceftriaxone is 0.71 ml in water for injections and 1% lidocaine hydrochloride solution. When adding 10 ml of water for injections, the final concentration of the reconstituted solution is 93.37 mg/ml. When adding 3.5 ml of 1% lidocaine hydrochloride solution, the final concentration of the reconstituted solution is 237.53 mg/ml.</p><p>The infusion line should be flushed after each administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Ceftriaxone Venus looks like and contents of the pack
Ceftriaxone Venus consists of a Powder for Solution for Injection or Infusion in a glass vial stoppered with a rubber stopper and sealed with an aluminium blue flip-off seal.
The product is almost white or yellowish, crystalline powder
After reconstitution it produces a clear solution.
Ceftriaxone Venus is available in pack of 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Venus Remedies Limited</strong></p><p>Hill Top Industrial Estate, Jharmajri EPIP,</p><p>Phase-I (Extn.), Bhatoli Kalan, Baddi, Dist. Solan, (H.P.), 173205, INDIA</p><p>Tel: +91172-3933107</p><p>E-mail: jsmahant@venusremedies.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سيفترياكسون مضاد حيوي يُعطى للبالغين والأطفال (بما في ذلك الأطفال حديثي الولادة). وهو يعمل عن طريق قتل البكتيريا المسببة للالتهابات. إنه ينتمي إلى مجموعة من الأدوية تسمى السيفالوسبورينات.</p><p dir="RTL">يستخدم سيفترياكسون لعلاج التهابات</p><p dir="RTL">&bull; الدماغ (التهاب السحايا).</p><p dir="RTL">&bull;الرئتين.</p><p dir="RTL">&bull; الأذن الوسطى.</p><p dir="RTL">&bull; البطن وجدار البطن (التهاب الصفاق).</p><p dir="RTL">&bull; المسالك البولية والكلى.</p><p dir="RTL">&bull; العظام والمفاصل.</p><p dir="RTL">&bull; الجلد أو الأنسجة الرخوة.</p><p dir="RTL">&bull;الدم.</p><p dir="RTL">&bull;القلب.</p><p dir="RTL">يمكن إعطاؤه:</p><p dir="RTL">&bull; لعلاج أنواع معينة من الأمراض المنقولة جنسياً (السيلان والزهري).</p><p dir="RTL">&bull; لعلاج المرضى الذين يعانون من انخفاض عدد خلايا الدم البيضاء (قلة العدلات) والذين يعانون من الحمى بسبب عدوى بكتيرية.</p><p dir="RTL">&bull; لعلاج التهابات الصدر عند البالغين المصابين بالتهاب الشعب الهوائية المزمن.</p><p dir="RTL">&bull; لعلاج مرض لايم (الناجم عن لدغات القراد) لدى البالغين والأطفال بما في ذلك الأطفال حديثي الولادة من عمر 15 يومًا.</p><p dir="RTL">&bull; لمنع الالتهابات أثناء الجراحة.</p><p dir="RTL">سيفترياكسون مضاد حيوي يُعطى للبالغين والأطفال (بما في ذلك الأطفال حديثي الولادة). وهو يعمل عن طريق قتل البكتيريا المسببة للالتهابات. إنه ينتمي إلى مجموعة من الأدوية تسمى السيفالوسبورينات.</p><p dir="RTL">يستخدم سيفترياكسون لعلاج التهابات</p><p dir="RTL">&bull; الدماغ (التهاب السحايا).</p><p dir="RTL">&bull;الرئتين.</p><p dir="RTL">&bull; الأذن الوسطى.</p><p dir="RTL">&bull; البطن وجدار البطن (التهاب الصفاق).</p><p dir="RTL">&bull; المسالك البولية والكلى.</p><p dir="RTL">&bull; العظام والمفاصل.</p><p dir="RTL">&bull; الجلد أو الأنسجة الرخوة.</p><p dir="RTL">&bull;الدم.</p><p dir="RTL">&bull;القلب.</p><p dir="RTL">يمكن إعطاؤه:</p><p dir="RTL">&bull; لعلاج أنواع معينة من الأمراض المنقولة جنسياً (السيلان والزهري).</p><p dir="RTL">&bull; لعلاج المرضى الذين يعانون من انخفاض عدد خلايا الدم البيضاء (قلة العدلات) والذين يعانون من الحمى بسبب عدوى بكتيرية.</p><p dir="RTL">&bull; لعلاج التهابات الصدر عند البالغين المصابين بالتهاب الشعب الهوائية المزمن.</p><p dir="RTL">&bull; لعلاج مرض لايم (الناجم عن لدغات القراد) لدى البالغين والأطفال بما في ذلك الأطفال حديثي الولادة من عمر 15 يومًا.</p><p dir="RTL">&bull; لمنع الالتهابات أثناء الجراحة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب ألا يتم إعطاؤك سيفترياكسون إذا:</strong></p><p dir="RTL">&bull; &nbsp;كانت لديك حساسية من سيفترياكسون أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&bull; عانيت من رد فعل تحسسي مفاجئ أو شديد تجاه بنسلين أو المضادات الحيوية المماثلة (مثل السيفالوسبورينات أو الكاربابينيمات أو المونوباكتام). تشمل العلامات تورمًا مفاجئًا في الحلق أو الوجه مما قد يجعل التنفس أو البلع صعبًا ، وتورمًا مفاجئًا في اليدين والقدمين والكاحلين ، وطفحًا جلديًا شديدًا يتطور بسرعة.</p><p dir="RTL">&bull; كانت لديك حساسية من ليدوكائين ويجب إعطاؤك سفترياكسون كحقنة في العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عدم إعطاء سيفترياكسون للأطفال الرضع إذا:</strong></p><p dir="RTL">&bull; كان الطفل مولودا سابقا لأوانه.</p><p dir="RTL">&bull; يكون الطفل حديث الولادة (حتى 28 يومًا من العمر) ولديه مشاكل معينة في الدم أو اليرقان (اصفرار الجلد أو بياض العينين) أو يجب إعطاؤه منتجًا يحتوي على كالسيوم في الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول سفترياكسون إذا:</p><p dir="RTL">&bull; لقد تلقيت مؤخرًا أو على وشك الحصول على منتجات تحتوي على الكالسيوم.</p><p dir="RTL">&bull; عانيت مؤخرًا من الإسهال بعد تناول دواء مضاد حيوي. عانيت من قبل من مشاكل في القناة الهضمية ، وخاصة التهاب القولون (التهاب الأمعاء).</p><p dir="RTL">&bull; كانت لديك مشاكل في الكبد أو الكلى.</p><p dir="RTL">&bull; كانت لديك حصوات في المرارة أو حصوات في الكلى</p><p dir="RTL">&bull; كانت لديك أمراض أخرى ، مثل فقر الدم الانحلالي (انخفاض في خلايا الدم الحمراء قد يجعل بشرتك شاحبة اللون الأصفر ويسبب الضعف أو ضيق التنفس).</p><p dir="RTL">&bull; كنت تتبع نظامًا غذائيًا منخفض الصوديوم.</p><p dir="RTL">&bull; كنت تعاني أو عانيت سابقًا من مجموعة من الأعراض التالية: طفح جلدي ، احمرار الجلد ، تقرحات في الشفتين والعينين والفم ، تقشر الجلد ، ارتفاع في درجة الحرارة ، أعراض شبيهة بالإنفلونزا ، زيادة مستويات إنزيمات الكبد التي لوحظت في اختبارات الدم و زيادة في نوع من خلايا الدم البيضاء (فرط الحمضات) وتضخم الغدد الليمفاوية (علامات لتفاعلات جلدية شديدة ، انظر أيضًا إلى القسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت بحاجة إلى فحص دم أو بول</strong></p><p dir="RTL">إذا تم إعطاؤك سفترياكسون لفترة طويلة ، فقد تحتاج إلى إجراء اختبارات دم منتظمة. يمكن أن يؤثر سيفترياكسون على نتائج اختبارات البول للسكر واختبار الدم المعروف باسم اختبار كومبس. إذا كنت ستخضع لاختبارات:</p><p dir="RTL">&bull; أخبر الشخص الذي أخذ العينة أنك قد تناولت سفترياكسون.</p><p dir="RTL">إذا كنت مصابًا بداء السكري أو كنت بحاجة إلى مراقبة مستوى الجلوكوز في الدم ، فيجب ألا تستخدم بعض أنظمة مراقبة نسبة الجلوكوز في الدم والتي قد تقدر نسبة الجلوكوز في الدم بشكل غير صحيح أثناء تلقيك لسفترياكسون. إذا كنت تستخدم مثل هذه الأنظمة ، فتحقق من تعليمات الاستخدام وأخبر طبيبك أو الصيدلي أو الممرضة. يجب استخدام طرق الاختبار البديلة إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أطفال</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل إعطاء طفلك سفترياكسون إذا:</p><p dir="RTL">&bull; تم إعطاؤه / إعطائها مؤخرًا منتجًا يحتوي على كالسيوم في وريده أو سيتم إعطاؤه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وسيفترياكسون</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">على وجه الخصوص ، أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL">&bull; نوع من المضادات الحيوية يسمى أمينوغليكوزيد.</p><p dir="RTL">&bull; مضاد حيوي يسمى كلورامفينيكول (يستخدم لعلاج الالتهابات ، وخاصة في العين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، تعتقدين أنك حامل أو تخططين لإنجاب طفل ، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">سينظر الطبيب في فائدة علاجك بسفترياكسون ضد المخاطر على طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>السياقة واستعمال الماكنات</strong></p><p dir="RTL">يمكن أن يسبب سيفترياكسون الدوخة. إذا شعرت بالدوار ، فلا تقد ولا تستخدم أي أدوات أو آلات. تحدث إلى طبيبك إذا واجهت هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صوديوم:</strong></p><p dir="RTL">يحتوي هذا الدواء على 82.8 مجم (1 جرام قارورة) من الصوديوم لكل جرعة. هذا يعادل 4.14-8.28٪ من الحد الأقصى الموصى به من المدخول الغذائي اليومي من صوديوم لشخص بالغ.</p><p dir="RTL"><strong>يجب ألا يتم إعطاؤك سيفترياكسون إذا:</strong></p><p dir="RTL">&bull; &nbsp;كانت لديك حساسية من سيفترياكسون أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&bull; عانيت من رد فعل تحسسي مفاجئ أو شديد تجاه بنسلين أو المضادات الحيوية المماثلة (مثل السيفالوسبورينات أو الكاربابينيمات أو المونوباكتام). تشمل العلامات تورمًا مفاجئًا في الحلق أو الوجه مما قد يجعل التنفس أو البلع صعبًا ، وتورمًا مفاجئًا في اليدين والقدمين والكاحلين ، وطفحًا جلديًا شديدًا يتطور بسرعة.</p><p dir="RTL">&bull; كانت لديك حساسية من ليدوكائين ويجب إعطاؤك سفترياكسون كحقنة في العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عدم إعطاء سيفترياكسون للأطفال الرضع إذا:</strong></p><p dir="RTL">&bull; كان الطفل مولودا سابقا لأوانه.</p><p dir="RTL">&bull; يكون الطفل حديث الولادة (حتى 28 يومًا من العمر) ولديه مشاكل معينة في الدم أو اليرقان (اصفرار الجلد أو بياض العينين) أو يجب إعطاؤه منتجًا يحتوي على كالسيوم في الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول سفترياكسون إذا:</p><p dir="RTL">&bull; لقد تلقيت مؤخرًا أو على وشك الحصول على منتجات تحتوي على الكالسيوم.</p><p dir="RTL">&bull; عانيت مؤخرًا من الإسهال بعد تناول دواء مضاد حيوي. عانيت من قبل من مشاكل في القناة الهضمية ، وخاصة التهاب القولون (التهاب الأمعاء).</p><p dir="RTL">&bull; كانت لديك مشاكل في الكبد أو الكلى.</p><p dir="RTL">&bull; كانت لديك حصوات في المرارة أو حصوات في الكلى</p><p dir="RTL">&bull; كانت لديك أمراض أخرى ، مثل فقر الدم الانحلالي (انخفاض في خلايا الدم الحمراء قد يجعل بشرتك شاحبة اللون الأصفر ويسبب الضعف أو ضيق التنفس).</p><p dir="RTL">&bull; كنت تتبع نظامًا غذائيًا منخفض الصوديوم.</p><p dir="RTL">&bull; كنت تعاني أو عانيت سابقًا من مجموعة من الأعراض التالية: طفح جلدي ، احمرار الجلد ، تقرحات في الشفتين والعينين والفم ، تقشر الجلد ، ارتفاع في درجة الحرارة ، أعراض شبيهة بالإنفلونزا ، زيادة مستويات إنزيمات الكبد التي لوحظت في اختبارات الدم و زيادة في نوع من خلايا الدم البيضاء (فرط الحمضات) وتضخم الغدد الليمفاوية (علامات لتفاعلات جلدية شديدة ، انظر أيضًا إلى القسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت بحاجة إلى فحص دم أو بول</strong></p><p dir="RTL">إذا تم إعطاؤك سفترياكسون لفترة طويلة ، فقد تحتاج إلى إجراء اختبارات دم منتظمة. يمكن أن يؤثر سيفترياكسون على نتائج اختبارات البول للسكر واختبار الدم المعروف باسم اختبار كومبس. إذا كنت ستخضع لاختبارات:</p><p dir="RTL">&bull; أخبر الشخص الذي أخذ العينة أنك قد تناولت سفترياكسون.</p><p dir="RTL">إذا كنت مصابًا بداء السكري أو كنت بحاجة إلى مراقبة مستوى الجلوكوز في الدم ، فيجب ألا تستخدم بعض أنظمة مراقبة نسبة الجلوكوز في الدم والتي قد تقدر نسبة الجلوكوز في الدم بشكل غير صحيح أثناء تلقيك لسفترياكسون. إذا كنت تستخدم مثل هذه الأنظمة ، فتحقق من تعليمات الاستخدام وأخبر طبيبك أو الصيدلي أو الممرضة. يجب استخدام طرق الاختبار البديلة إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أطفال</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل إعطاء طفلك سفترياكسون إذا:</p><p dir="RTL">&bull; تم إعطاؤه / إعطائها مؤخرًا منتجًا يحتوي على كالسيوم في وريده أو سيتم إعطاؤه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وسيفترياكسون</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">على وجه الخصوص ، أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL">&bull; نوع من المضادات الحيوية يسمى أمينوغليكوزيد.</p><p dir="RTL">&bull; مضاد حيوي يسمى كلورامفينيكول (يستخدم لعلاج الالتهابات ، وخاصة في العين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، تعتقدين أنك حامل أو تخططين لإنجاب طفل ، اسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">سينظر الطبيب في فائدة علاجك بسفترياكسون ضد المخاطر على طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>السياقة واستعمال الماكنات</strong></p><p dir="RTL">يمكن أن يسبب سيفترياكسون الدوخة. إذا شعرت بالدوار ، فلا تقد ولا تستخدم أي أدوات أو آلات. تحدث إلى طبيبك إذا واجهت هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صوديوم:</strong></p><p dir="RTL">يحتوي هذا الدواء على 82.8 مجم (1 جرام قارورة) من الصوديوم لكل جرعة. هذا يعادل 4.14-8.28٪ من الحد الأقصى الموصى به من المدخول الغذائي اليومي من صوديوم لشخص بالغ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادة ما يتم إعطاء سفترياكسون من قبل الطبيب أو الممرضة. يمكن إعطاؤه كـ</p><p dir="RTL">&bull; بالتنقيط (التسريب في الوريد) أو كحقنة مباشرة في الوريد أو</p><p dir="RTL">&bull; في العضلة.</p><p dir="RTL">يتم تحضير سيفترياكسون من قبل الطبيب أو الصيدلي أو الممرضة ولن يتم مزجه أو إعطاؤه لك في نفس وقت الحقن المحتوية على كالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة المعتادة</strong></p><p dir="RTL">سيقرر طبيبك الجرعة المناسبة لك من سيفترياكسون. تعتمد الجرعة على شدة العدوى ونوعها ؛ ما إذا كنت تتناول أي مضادات حيوية أخرى ؛ وزنك وعمرك مدى جودة عمل الكلى والكبد. يعتمد عدد الأيام أو الأسابيع التي تتناول فيها سفترياكسون على نوع العدوى التي تعاني منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">البالغون وكبار السن والأطفال الذين تبلغ أعمارهم 12 عامًا فأكثر ويزيد وزن جسمهم عن 50 كيلوجرامًا أو يساويها:</p><p dir="RTL">&bull; 1 إلى 2 جم مرة واحدة يوميًا حسب شدة العدوى ونوعها. إذا كنت تعاني من عدوى شديدة ، فسوف يعطيك طبيبك جرعة أعلى (تصل إلى 4 جم مرة واحدة في اليوم). إذا كانت جرعتك اليومية أعلى من 2 جم ، فقد تحصل عليها كجرعة واحدة مرة واحدة يوميًا أو كجرعتين منفصلتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حديثو الولادة والرضع والأطفال الذين تتراوح أعمارهم بين 15 يومًا و 12 عامًا بوزن أقل من 50 كجم</p><p dir="RTL">&bull; 50-80 مجم سيفترياكسون لكل كيلوجرام من وزن جسم الطفل مرة واحدة في اليوم حسب شدة العدوى ونوعها. إذا كنت تعاني من عدوى شديدة ، فسوف يعطيك طبيبك جرعة أعلى تصل إلى 100 مجم لكل كيلوغرام من وزن الجسم بحد أقصى 4 جرام مرة واحدة في اليوم. إذا كانت جرعتك اليومية أعلى من 2 جم ، فقد تحصل عليها كجرعة واحدة مرة واحدة يوميًا أو كجرعتين منفصلتين.</p><p dir="RTL">&bull; يجب إعطاء الأطفال الذين يبلغ وزن جسمهم 50 كجم أو أكثر جرعة البالغين المعتادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال حديثو الولادة (0-14 يوم)</p><p dir="RTL">&bull; 20-50 مجم سيفترياكسون لكل كيلوجرام من وزن جسم الطفل مرة واحدة في اليوم حسب شدة العدوى ونوعها.</p><p dir="RTL">&bull; يجب ألا تزيد الجرعة اليومية القصوى عن 50 مجم لكل كيلو جرام من وزن الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأشخاص الذين يعانون من مشاكل في الكبد والكلى</p><p dir="RTL">قد يتم إعطاؤك جرعة مختلفة عن الجرعة المعتادة. سيقرر طبيبك كمية سيفترياكسون التي ستحتاج &nbsp;إليها وسيقوم بفحصك عن كثب اعتمادًا على شدة أمراض الكبد والكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك سفترياكسون أكثر مما ينبغي</strong></p><p dir="RTL">إذا تلقيت عن طريق الخطأ أكثر من الجرعة الموصوفة لك ، فاتصل بطبيبك أو أقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام سيفترياكسون</strong></p><p dir="RTL">إذا فاتتك حقنة ، يجب أن تأخذها في أقرب وقت ممكن. ومع ذلك ، إذا حان وقت الحقن التالي تقريبًا ، فتجاوز الحقنة الفائتة. لا تأخذ جرعة مضاعفة (حقنتين في نفس الوقت) لتعويض الجرعة الفائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام سيفترياكسون</strong></p><p dir="RTL">لا تتوقف عن تناول سيفترياكسون ما لم يخبرك طبيبك بذلك. إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو ممرضتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عادة ما يتم إعطاء سفترياكسون من قبل الطبيب أو الممرضة. يمكن إعطاؤه كـ</p><p dir="RTL">&bull; بالتنقيط (التسريب في الوريد) أو كحقنة مباشرة في الوريد أو</p><p dir="RTL">&bull; في العضلة.</p><p dir="RTL">يتم تحضير سيفترياكسون من قبل الطبيب أو الصيدلي أو الممرضة ولن يتم مزجه أو إعطاؤه لك في نفس وقت الحقن المحتوية على كالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة المعتادة</strong></p><p dir="RTL">سيقرر طبيبك الجرعة المناسبة لك من سيفترياكسون. تعتمد الجرعة على شدة العدوى ونوعها ؛ ما إذا كنت تتناول أي مضادات حيوية أخرى ؛ وزنك وعمرك مدى جودة عمل الكلى والكبد. يعتمد عدد الأيام أو الأسابيع التي تتناول فيها سفترياكسون على نوع العدوى التي تعاني منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">البالغون وكبار السن والأطفال الذين تبلغ أعمارهم 12 عامًا فأكثر ويزيد وزن جسمهم عن 50 كيلوجرامًا أو يساويها:</p><p dir="RTL">&bull; 1 إلى 2 جم مرة واحدة يوميًا حسب شدة العدوى ونوعها. إذا كنت تعاني من عدوى شديدة ، فسوف يعطيك طبيبك جرعة أعلى (تصل إلى 4 جم مرة واحدة في اليوم). إذا كانت جرعتك اليومية أعلى من 2 جم ، فقد تحصل عليها كجرعة واحدة مرة واحدة يوميًا أو كجرعتين منفصلتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حديثو الولادة والرضع والأطفال الذين تتراوح أعمارهم بين 15 يومًا و 12 عامًا بوزن أقل من 50 كجم</p><p dir="RTL">&bull; 50-80 مجم سيفترياكسون لكل كيلوجرام من وزن جسم الطفل مرة واحدة في اليوم حسب شدة العدوى ونوعها. إذا كنت تعاني من عدوى شديدة ، فسوف يعطيك طبيبك جرعة أعلى تصل إلى 100 مجم لكل كيلوغرام من وزن الجسم بحد أقصى 4 جرام مرة واحدة في اليوم. إذا كانت جرعتك اليومية أعلى من 2 جم ، فقد تحصل عليها كجرعة واحدة مرة واحدة يوميًا أو كجرعتين منفصلتين.</p><p dir="RTL">&bull; يجب إعطاء الأطفال الذين يبلغ وزن جسمهم 50 كجم أو أكثر جرعة البالغين المعتادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال حديثو الولادة (0-14 يوم)</p><p dir="RTL">&bull; 20-50 مجم سيفترياكسون لكل كيلوجرام من وزن جسم الطفل مرة واحدة في اليوم حسب شدة العدوى ونوعها.</p><p dir="RTL">&bull; يجب ألا تزيد الجرعة اليومية القصوى عن 50 مجم لكل كيلو جرام من وزن الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأشخاص الذين يعانون من مشاكل في الكبد والكلى</p><p dir="RTL">قد يتم إعطاؤك جرعة مختلفة عن الجرعة المعتادة. سيقرر طبيبك كمية سيفترياكسون التي ستحتاج &nbsp;إليها وسيقوم بفحصك عن كثب اعتمادًا على شدة أمراض الكبد والكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك سفترياكسون أكثر مما ينبغي</strong></p><p dir="RTL">إذا تلقيت عن طريق الخطأ أكثر من الجرعة الموصوفة لك ، فاتصل بطبيبك أو أقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام سيفترياكسون</strong></p><p dir="RTL">إذا فاتتك حقنة ، يجب أن تأخذها في أقرب وقت ممكن. ومع ذلك ، إذا حان وقت الحقن التالي تقريبًا ، فتجاوز الحقنة الفائتة. لا تأخذ جرعة مضاعفة (حقنتين في نفس الوقت) لتعويض الجرعة الفائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام سيفترياكسون</strong></p><p dir="RTL">لا تتوقف عن تناول سيفترياكسون ما لم يخبرك طبيبك بذلك. إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو ممرضتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد تحدث الآثار الجانبية التالية مع هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات حساسية شديدة (غير معروف ، لا يمكن تقدير التكرار من البيانات المتاحة)</strong></p><p dir="RTL">إذا كان لديك رد فعل تحسسي شديد ، أخبر الطبيب على الفور.</p><p dir="RTL">قد تشمل العلامات:</p><p dir="RTL">&bull; انتفاخ مفاجئ في الوجه أو الحلق أو الشفتين أو الفم. قد يؤدي ذلك إلى صعوبة التنفس أو البلع.</p><p dir="RTL">&bull; انتفاخ مفاجئ في اليدين والقدمين والكاحلين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات جلدية شديدة (غير معروفة ، لا يمكن تقدير التكرار من البيانات المتاحة)</strong></p><p dir="RTL">إذا أصبت برد فعل جلدي شديد ، أخبر الطبيب على الفور.</p><p dir="RTL">قد تشمل العلامات:</p><p dir="RTL">&bull; طفح جلدي حاد يتطور بسرعة مع ظهور بثور أو تقشير في الجلد وربما ظهور بثور في الفم (متلازمة ستيفنز جونسون وانحلال البشرة النخري السمي المعروف أيضًا باسم SJS و TEN).</p><p dir="RTL">&bull; مزيج من أي من الأعراض التالية: طفح جلدي واسع الانتشار ، وارتفاع درجة حرارة الجسم ، وارتفاع إنزيمات الكبد ، واضطرابات الدم (فرط الحمضات) ، وتضخم الغدد الليمفاوية وتأثر أعضاء الجسم الأخرى (تفاعل الدواء مع فرط الحمضات والأعراض الجهازية التي تُعرف أيضًا باسم DRESS أو متلازمة فرط الحساسية للمخدرات).</p><p dir="RTL">&bull; رد فعل ياريش هركسهايمر الذي يسبب الحمى والقشعريرة والصداع وآلام العضلات والطفح الجلدي التي عادة ما تكون ذاتية الشفاء. يحدث هذا بعد فترة وجيزة من بدء علاج سيفترياكسون للعدوى باللولبيات مثل مرض لايم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية المحتملة الأخرى:</p><p dir="RTL"><strong>شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص)</strong></p><p dir="RTL"><strong>&bull; </strong>تشوهات في خلايا الدم البيضاء (مثل انخفاض عدد الكريات البيض وزيادة الحمضات) والصفائح الدموية (نقص الصفيحات).</p><p dir="RTL">&bull; براز رخو أو إسهال.</p><p dir="RTL">&bull; تغيرات في نتائج فحوصات الدم لوظائف الكبد.</p><p dir="RTL">&bull; طفح جلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص)</strong></p><p dir="RTL">&bull; الالتهابات الفطرية (مثل مرض القلاع).</p><p dir="RTL">&bull; انخفاض في عدد خلايا الدم البيضاء (قلة المحببات).</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">&bull; مشاكل في طريقة تجلط الدم. قد تشمل العلامات ظهور كدمات بسهولة وألم وتورم في مفاصلك.</p><p dir="RTL">&bull; صداع الراس.</p><p dir="RTL">&bull; دوار.</p><p dir="RTL">&bull; الشعور بالمرض أو المرض.</p><p dir="RTL">&bull; حكة (حكة).</p><p dir="RTL">&bull; ألم أو شعور حارق على طول الوريد حيث تم إعطاء سفترياكسون. ألم في مكان الحقن.</p><p dir="RTL">&bull; ارتفاع في درجة الحرارة (حمى).</p><p dir="RTL">&bull; اختلال في اختبار وظائف الكلى (زيادة الكرياتينين في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تظهر لدى حتى 1 من كل 1000 شخص)</strong></p><p dir="RTL">&bull; التهاب الأمعاء الغليظة (القولون). تشمل العلامات إسهالًا مصحوبًا بدم ومخاط عادةً وآلام في المعدة وحمى.</p><p dir="RTL">&bull; صعوبة في التنفس (تشنج قصبي).</p><p dir="RTL">&bull; طفح جلدي متكتل (خلايا النحل) قد يغطي جزءًا كبيرًا من جسمك ، مما يؤدي إلى الشعور بالحكة والتورم.</p><p dir="RTL">&bull; دم أو سكر في البول.</p><p dir="RTL">&bull; وذمة (تراكم السوائل).</p><p dir="RTL">&bull; ارتعاش.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة)</strong></p><p dir="RTL">&bull; عدوى ثانوية قد لا تستجيب للمضاد الحيوي الذي سبق وصفه</p><p dir="RTL">&bull; شكل من أشكال فقر الدم حيث يتم تدمير خلايا الدم الحمراء (فقر الدم الانحلالي).</p><p dir="RTL">&bull; انخفاض حاد في خلايا الدم البيضاء (ندرة المحببات).</p><p dir="RTL">&bull; التشنجات.</p><p dir="RTL">&bull; الدوار (الإحساس بالدوران).</p><p dir="RTL">&bull; التهاب البنكرياس (pancreatitis). تشمل العلامات ألمًا شديدًا في المعدة ينتشر إلى ظهرك.</p><p dir="RTL">&bull; التهاب الغشاء المخاطي للفم (التهاب الفم).</p><p dir="RTL">&bull; التهاب اللسان (التهاب اللسان). تشمل العلامات تورم واحمرار وألم اللسان.</p><p dir="RTL">&bull; مشاكل في المرارة ، والتي قد تسبب الألم والشعور بالمرض و كون المرض.</p><p dir="RTL">&bull; حالة عصبية قد تحدث عند حديثي الولادة المصابين باليرقان الشديد (اليرقان).</p><p dir="RTL">&bull; مشاكل الكلى الناتجة عن ترسبات الكالسيوم سيفترياكسون. قد يكون هناك ألم عند التبول أو انخفاض كمية البول.</p><p dir="RTL">&bull; نتيجة إيجابية خاطئة في اختبار كومبس (اختبار لبعض مشاكل الدم).</p><p dir="RTL">&bull; نتيجة إيجابية خاطئة للجالاكتوزيميا (تراكم غير طبيعي لسكر الجالاكتوز).</p><p dir="RTL">&bull; قد يتداخل سيفترياكسون مع بعض أنواع اختبارات جلوكوز الدم - يرجى مراجعة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا عانيت من أي آثار جانبية ، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد تحدث الآثار الجانبية التالية مع هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات حساسية شديدة (غير معروف ، لا يمكن تقدير التكرار من البيانات المتاحة)</strong></p><p dir="RTL">إذا كان لديك رد فعل تحسسي شديد ، أخبر الطبيب على الفور.</p><p dir="RTL">قد تشمل العلامات:</p><p dir="RTL">&bull; انتفاخ مفاجئ في الوجه أو الحلق أو الشفتين أو الفم. قد يؤدي ذلك إلى صعوبة التنفس أو البلع.</p><p dir="RTL">&bull; انتفاخ مفاجئ في اليدين والقدمين والكاحلين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات جلدية شديدة (غير معروفة ، لا يمكن تقدير التكرار من البيانات المتاحة)</strong></p><p dir="RTL">إذا أصبت برد فعل جلدي شديد ، أخبر الطبيب على الفور.</p><p dir="RTL">قد تشمل العلامات:</p><p dir="RTL">&bull; طفح جلدي حاد يتطور بسرعة مع ظهور بثور أو تقشير في الجلد وربما ظهور بثور في الفم (متلازمة ستيفنز جونسون وانحلال البشرة النخري السمي المعروف أيضًا باسم SJS و TEN).</p><p dir="RTL">&bull; مزيج من أي من الأعراض التالية: طفح جلدي واسع الانتشار ، وارتفاع درجة حرارة الجسم ، وارتفاع إنزيمات الكبد ، واضطرابات الدم (فرط الحمضات) ، وتضخم الغدد الليمفاوية وتأثر أعضاء الجسم الأخرى (تفاعل الدواء مع فرط الحمضات والأعراض الجهازية التي تُعرف أيضًا باسم DRESS أو متلازمة فرط الحساسية للمخدرات).</p><p dir="RTL">&bull; رد فعل ياريش هركسهايمر الذي يسبب الحمى والقشعريرة والصداع وآلام العضلات والطفح الجلدي التي عادة ما تكون ذاتية الشفاء. يحدث هذا بعد فترة وجيزة من بدء علاج سيفترياكسون للعدوى باللولبيات مثل مرض لايم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية المحتملة الأخرى:</p><p dir="RTL"><strong>شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص)</strong></p><p dir="RTL"><strong>&bull; </strong>تشوهات في خلايا الدم البيضاء (مثل انخفاض عدد الكريات البيض وزيادة الحمضات) والصفائح الدموية (نقص الصفيحات).</p><p dir="RTL">&bull; براز رخو أو إسهال.</p><p dir="RTL">&bull; تغيرات في نتائج فحوصات الدم لوظائف الكبد.</p><p dir="RTL">&bull; طفح جلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص)</strong></p><p dir="RTL">&bull; الالتهابات الفطرية (مثل مرض القلاع).</p><p dir="RTL">&bull; انخفاض في عدد خلايا الدم البيضاء (قلة المحببات).</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">&bull; مشاكل في طريقة تجلط الدم. قد تشمل العلامات ظهور كدمات بسهولة وألم وتورم في مفاصلك.</p><p dir="RTL">&bull; صداع الراس.</p><p dir="RTL">&bull; دوار.</p><p dir="RTL">&bull; الشعور بالمرض أو المرض.</p><p dir="RTL">&bull; حكة (حكة).</p><p dir="RTL">&bull; ألم أو شعور حارق على طول الوريد حيث تم إعطاء سفترياكسون. ألم في مكان الحقن.</p><p dir="RTL">&bull; ارتفاع في درجة الحرارة (حمى).</p><p dir="RTL">&bull; اختلال في اختبار وظائف الكلى (زيادة الكرياتينين في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تظهر لدى حتى 1 من كل 1000 شخص)</strong></p><p dir="RTL">&bull; التهاب الأمعاء الغليظة (القولون). تشمل العلامات إسهالًا مصحوبًا بدم ومخاط عادةً وآلام في المعدة وحمى.</p><p dir="RTL">&bull; صعوبة في التنفس (تشنج قصبي).</p><p dir="RTL">&bull; طفح جلدي متكتل (خلايا النحل) قد يغطي جزءًا كبيرًا من جسمك ، مما يؤدي إلى الشعور بالحكة والتورم.</p><p dir="RTL">&bull; دم أو سكر في البول.</p><p dir="RTL">&bull; وذمة (تراكم السوائل).</p><p dir="RTL">&bull; ارتعاش.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة)</strong></p><p dir="RTL">&bull; عدوى ثانوية قد لا تستجيب للمضاد الحيوي الذي سبق وصفه</p><p dir="RTL">&bull; شكل من أشكال فقر الدم حيث يتم تدمير خلايا الدم الحمراء (فقر الدم الانحلالي).</p><p dir="RTL">&bull; انخفاض حاد في خلايا الدم البيضاء (ندرة المحببات).</p><p dir="RTL">&bull; التشنجات.</p><p dir="RTL">&bull; الدوار (الإحساس بالدوران).</p><p dir="RTL">&bull; التهاب البنكرياس (pancreatitis). تشمل العلامات ألمًا شديدًا في المعدة ينتشر إلى ظهرك.</p><p dir="RTL">&bull; التهاب الغشاء المخاطي للفم (التهاب الفم).</p><p dir="RTL">&bull; التهاب اللسان (التهاب اللسان). تشمل العلامات تورم واحمرار وألم اللسان.</p><p dir="RTL">&bull; مشاكل في المرارة ، والتي قد تسبب الألم والشعور بالمرض و كون المرض.</p><p dir="RTL">&bull; حالة عصبية قد تحدث عند حديثي الولادة المصابين باليرقان الشديد (اليرقان).</p><p dir="RTL">&bull; مشاكل الكلى الناتجة عن ترسبات الكالسيوم سيفترياكسون. قد يكون هناك ألم عند التبول أو انخفاض كمية البول.</p><p dir="RTL">&bull; نتيجة إيجابية خاطئة في اختبار كومبس (اختبار لبعض مشاكل الدم).</p><p dir="RTL">&bull; نتيجة إيجابية خاطئة للجالاكتوزيميا (تراكم غير طبيعي لسكر الجالاكتوز).</p><p dir="RTL">&bull; قد يتداخل سيفترياكسون مع بعض أنواع اختبارات جلوكوز الدم - يرجى مراجعة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا عانيت من أي آثار جانبية ، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الكرتون وعلى الملصق الزجاجي أو الزجاجة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية. احتفظ بالقارورة في الكرتون الخارجي لحمايتها من الضوء. .</p><p dir="RTL">احتفظ بالقنينة أو الزجاجة في الكرتون الخارجي لحمايتها من الضوء.</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام للمنتج المعاد تكوينه لمدة 6 ساعات على الأقل عند أو أقل من 25 درجة مئوية أو 24 ساعة عند 2-8 درجة مئوية.</p><p dir="RTL">من وجهة نظر ميكروبيولوجية ، يجب استخدام المنتج على الفور. إذا لم يتم استخدامه على الفور ، فإن أوقات التخزين أثناء الاستخدام وشروطه قبل الاستخدام تقع على عاتق المستخدم ولن تزيد عن 24 ساعة عند 2 إلى 8 درجات مئوية ، ما لم يتم إعادة التركيب / التخفيف في ظروف تعقيم خاضعة للرقابة والتحقق من صحتها.</p><p dir="RTL">لا يجوز التخلص من الأدوية في مياه الصرف الصحي. اطلب من الصيدلي التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الكرتون وعلى الملصق الزجاجي أو الزجاجة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية. احتفظ بالقارورة في الكرتون الخارجي لحمايتها من الضوء. .</p><p dir="RTL">احتفظ بالقنينة أو الزجاجة في الكرتون الخارجي لحمايتها من الضوء.</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام للمنتج المعاد تكوينه لمدة 6 ساعات على الأقل عند أو أقل من 25 درجة مئوية أو 24 ساعة عند 2-8 درجة مئوية.</p><p dir="RTL">من وجهة نظر ميكروبيولوجية ، يجب استخدام المنتج على الفور. إذا لم يتم استخدامه على الفور ، فإن أوقات التخزين أثناء الاستخدام وشروطه قبل الاستخدام تقع على عاتق المستخدم ولن تزيد عن 24 ساعة عند 2 إلى 8 درجات مئوية ، ما لم يتم إعادة التركيب / التخفيف في ظروف تعقيم خاضعة للرقابة والتحقق من صحتها.</p><p dir="RTL">لا يجوز التخلص من الأدوية في مياه الصرف الصحي. اطلب من الصيدلي التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيفترياكسون 1 جم مسحوق للحقن أو التسريب:</p><p dir="RTL">المادة الفعالة هي سيفترياكسون.</p><p dir="RTL">تحتوي كل قنينة على سيفترياكسون صوديوم ما يعادل سيفترياكسون 1 جرام</p><p dir="RTL">يحتوي كل 1 جرام من سيفترياكسون صوديوم على حوالي 3.6 ملي مول (82.8 مجم) صوديوم.</p><p dir="RTL">لا تحتوي القارورة على مكونات أخرى.</p><p dir="RTL">حجم الإزاحة من 1 غرام من سيفترياكسون هو 0.71 مل في الماء للحقن و 1 ٪ محلول ليدوكائين هيدروكلوريد. عند إضافة 10 مل من الماء للحقن ، يكون التركيز النهائي للمحلول المعاد تركيبه 93.37 مجم / مل. عند إضافة 3.5 مل من محلول ليدوكائين هيدروكلوريد 1٪ ، يكون التركيز النهائي للمحلول المعاد تركيبه 237.53 مجم / مل.</p><p dir="RTL">يجب شطف خط التسريب بعد كل إعطاء.</p><p dir="RTL">سيفترياكسون 1 جم مسحوق للحقن أو التسريب:</p><p dir="RTL">المادة الفعالة هي سيفترياكسون.</p><p dir="RTL">تحتوي كل قنينة على سيفترياكسون صوديوم ما يعادل سيفترياكسون 1 جرام</p><p dir="RTL">يحتوي كل 1 جرام من سيفترياكسون صوديوم على حوالي 3.6 ملي مول (82.8 مجم) صوديوم.</p><p dir="RTL">لا تحتوي القارورة على مكونات أخرى.</p><p dir="RTL">حجم الإزاحة من 1 غرام من سيفترياكسون هو 0.71 مل في الماء للحقن و 1 ٪ محلول ليدوكائين هيدروكلوريد. عند إضافة 10 مل من الماء للحقن ، يكون التركيز النهائي للمحلول المعاد تركيبه 93.37 مجم / مل. عند إضافة 3.5 مل من محلول ليدوكائين هيدروكلوريد 1٪ ، يكون التركيز النهائي للمحلول المعاد تركيبه 237.53 مجم / مل.</p><p dir="RTL">يجب شطف خط التسريب بعد كل إعطاء.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يتكون سيفترياكسون من مسحوق للمحلول للحقن أو التسريب في قنينة زجاجية سدادة بسدادة مطاطية ومختومة بختم قلاب من الألومنيوم الأزرق.</p><p dir="RTL">بعد إعادة التركيب ينتج حلاً واضحًا.</p><p dir="RTL">يتوفر سيفترياكسون في عبوة تحتوي على قنينة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة فينوس ريميديس&nbsp;المحدودة</strong></p><p dir="RTL">منطقة هيل توب الصناعية الشرقية، جرماجري EPIP,</p><p dir="RTL">فيس - 1(إيكستن.)، بهاتولي كالان بادي بمديرية سولان&nbsp; هيماجل براديش 173205، الهند</p><p dir="RTL">الهاتف: +91172-3933107</p><p dir="RTL">البريد الإلكتروني:&nbsp; jsmahant@venusremedies.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ceftriaxone 1 g Powder for Solution for Injection or Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ceftriaxone 1 g Powder for Solution for Injection or Infusion
Each vial contains Ceftriaxone Sodium equivalent to Ceftriaxone 1 g
Each gram of ceftriaxone sodium contains approximately 3.6 mmol (82.8 mg) sodium. For the 	full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Solution for Injection or Infusion.
Almost white or yellowish, crystalline powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftriaxone is indicated for the treatment of the following infections in adults and children &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; including term neonates (from birth):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial Meningitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community acquired pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hospital acquired pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute otitis media</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intra-abdominal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections (including pyelonephritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of bones and joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissue infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gonorrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syphilis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial endocarditis</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Ceftriaxone may be used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For Pre-operative prophylaxis of surgical site infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; associated with, any of the infections listed above</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ceftriaxone should be co-administered with other antibacterial agents whenever the possible &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; range of causative bacteria would not fall within its spectrum (see section 4.4).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consideration should be given to official guidelines on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose depends on the severity, susceptibility, site and type of infection and on the age and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepato-renal function of the patient.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doses recommended in the tables below are the generally recommended doses in these &nbsp;&nbsp;&nbsp; indications. In particularly severe cases, doses at the higher end of the recommended range &nbsp;&nbsp; should be considered.</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Adults and children over 12 years of age (&ge; 50</u> <u>kg)</u></em></p><p><img alt="" width="500" height="335" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAtEAAAHjCAIAAABq8dRrAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAHRMSURBVHhe7b2tklzH0oYrbCZqKmooaC5mKmYuZHaA4kT4QBFjAXNFmCvCXOELUJjLVyBfwz6P511+v3StH/X0dOfUjN4nKjrqJysrK2utyuweee8n/wshhBBCuD7JOUIIIYTQQXKOEEIIIXSQnCOEEEIIHSTnCCGEEEIH/5dz/H8hhBBCCJdmyTOGnGOphQsRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfi6Qczx58o3Ls2ff0fPp019v3vyi0WM88cWLH5au0/BaD4ULBrkPH/6w3zbLic7/mtFx8NQNrnv16icJnAgPoecuXf/7H0pockxL+xLwTqHztq9JCCFMxZ1yDt2t9XrVzUg5Jex5ri5uKTnl0n/37jfPXbqm5+I5h+p2hf2GM6+Xc9w2JF+E01PY0/nPc3/jwLNTWL8FS/tfhXf3VdWAB6QWbyxdIYTw0Dg/51hftYZvY18MEjVv0NdNLlM6T7z6kT87SNwLl805cJTq65zjGhFaoPZevmef8jjdlqvmHOq5Y0I8vAvK5vM7RwjhQXNmzqGv2pTNYMDorXKO2vOwMonTuWDOUVnnHFeCA2WV/pinfPRh5Rx353G/CyGEr5Yzcw7fs6d8mVPYoDguKoC50Bx6mKIvdiqsohX5dLpD8e/MtdM3de2s+mvgRNj91ubdMeqJNl442FOWrkP6c47qdrtiGSsbZ4NL1w3VIcxSpx2iQrNuv/oZYQ9VP0MVk6vrEVeFPohqDAUZ9d+dg5yj2lmt0qiwDLPsHA1tOtZnYTFR+7279buwaUbt9Ol/0aXgTooXDSGEBs7MOXyx1rtsE0kipmvaF7EvRPpp8qn711c/WIZOXcQa9aWs1SWm21NK+Pxn/g2S9MRqsGyTAbUODgZMGUwFGcAndSZK+TH9OQdoCPPYjnakLaifSnWd+uU6q5W7mCX/VMc61qpTAhT6maW6NUuhjJQl6kezJNVTV/EzQ5GrL8hBzgHevjpVt4dtFXXvVM3aY5u1KWZJrReioroVUlFTLrIk2NtqSpUcVetgbRLW6h6VHteZq3oIITRw3ZxjuGQ1RXUNUXTPwvqetYxuRgR07yvkU7R6XUVKfMOCr2AEauiycjV1F3tiNcYabGptaqIsPOAecw5tSpJU5D11KkAOB8S+rNbniwzN6lhtnKJmFdiLu/KSDNCQfashud2rrPVcihNzDh2xjLeHByMHPww2S5WUD962T+wELQdaopq06W0t4RU1/dilam4+LSGEcG3OzDl0c1F8S27ii7IWrkiGhmsd1vfsWkYoaFGkyqiTUpXAcF8LdVpykKnGDJe4m7V8MSjeY84xDPnsalnGbrArKPa8ghxz1YTBY1VgiLtu1iKrBt8Oz8Cg54KckXN472raq4MfBps1WpUP+GGmyAkw+AHqKl5C8sOKJ7qU4sMNIYQezsw5fCkfB4ODC3e41mF9z65lhK9pLlD1aCHE1krA9yxiS9fKtnqnQ9UzXOJuDlYdM1vOwefSLmhryK89jyuGWYPHqsAQBd2UAyuDb6vbYdBzQZpzDo9WJInawQkw+AGqnsGfw4rHLhXq9JQQQujhzJwDdPNSlnaBy06XNTeaZLgWNWSGax10q9bLcS0jBrVqauLmDYuAr2xbUmeBBJiuZtUzXOLDFX8i8+QcdsXS/hfvi/2uPS+H2D8w6MFXFli7SM21kYNvq9uFRm/l6lO4S84xuGLww7B3PWYUe9Kon7UGJ4B0VpOGVap8PTiaX3SpkNi6P4QQrsf5OQfoaqMs7Ru44xxafBvW+5pOKsO1Dr5nEdB9vZYRvselqt6q6h8ua2nTEEX9gBhNKa91qDp1O1McEjRK8V60xAHz5Bzejvu1zeptnYXqktGW+aRHfrCMBORABKj73O2WQaGWUEX90lndLjSKHoq8fRHuknN4VPaoboH13tW0fsSQqRtH0nXJyF1MQVJ6Bm/LBq1Y63DsUvR4FTo9K4QQGrhTzgG+4Fx0TRtfwXXUl6zK5u08TPRFOaxIj+5cFWvmMq2SvrJVUC5trLXurMK6sl0sU/uRV+cB18g5bIBLdX61cAgtgw+9KffUA9Ion2pKVfW5Qpebg6t9cINX6bFOd7pul3ohPyQXQcdRV1Rh3cE5VcY2VP9oX/ZhfaK8d/dQfEaWrNo8qqbehcHbEqiddtcXXcqnDKZYVQgh9HDXnCOcSFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPq5bs7x6tVPT558s1kWicn49OkvbHvz5pelfTnu6NIPH/6w665h3lS8e/cb22TLS7sgPyCwtM8lOUcIIfRz3ZxDPHv2nYKlmoooFDIS9cyDco67h7Q1d3GpEw6ZR1kGHil6Qtjs0i7IFZvpyK1IzhFCCP3cQ84BTjvm+cr+4sUPCmbKhGTzZtg7j7u41D8XUecT29T/+PA22bISLG/WJ6IDsuR5JOcIIYR+7ifngM3Oe0Q5x1CWsUtwqZzjcWPPu3AuGvID4+J05AySc4QQQj/3lnM4jvp3cv/hgDKEkxpv6k8jNVEY/iDifhdP9K8sFPUY/XQ/1b/nGJIhLMQ81eUl90vejnW0FnXX+rVA2xy8YVfr5wRRj8YLuQc9nuVRUY2nWfVQEHZPXU4bHFQJWTuc9Rkk5wghhH7uP+dQ/HDsGeqgCESn6oqUgFoFXYKT5BWlPL2GNAcwaZMSaxAyiSkyeOm9EHdxqX21tP+N5bKz7kj93rgDuWSUhajuKTDoV91z5V7NtYuo27fqsUk3k/5B5jFdiYKGpI3i1ZnrtQAxipRrUaMlqFjb2STnCCGEfmbJOdR0jNEUhaVhyEiG6Q5jVOh3TFVolJijWpWUZn9pZglFMvVr+qW4Rs6hHoVndmQ/SEYbZ1QCkrE85cScQ2tJWNmDhgY9UiIHQs0zJOmh4YBshqBf+pH3FEFTj4FMUud5JOcIIYR+7j/nUCCUjOOcmgowIEmK8wPjAObRIaRVzY7KtQwx70pcI+dga0v7huoKF7as8E+RQ4ZcAQb9qvss1KxF5zLoGZSoOVhoJKklvFAnyTlCCKGfe8s5hs6aGbjpnAMc0iyjmIeMMwlnJGrS77iozMaSanbSmXMs7X+5SM5hYXNKzuHmgE3FNlnVTHKOEELo535yDsd+RzIFUcc5TRninIOcmqoTtKzNOQd4UYqj2jrcttGQczi3GDKqIdNaO8EZgJqqD2dR8z8x6BmMtM7BGOG5a7U9JOcIIYR+7iHncLxxVAN3DnUgejk6EqIUaGue4fDmnIOemn9UFK0prEJT0zV0VRpyDpCY+5mokK8jkMOdmnjjdiA+8ahPZ3AvMkoUfEzSszZSTRvDLPlcSH7vmK5Nco4QQujnujmH49BQ1sESHMMGAUJa1bP0llTGQZFCiK16XBxBwWnH0H9VznZptZbCBut+KYvcv9ShGtHdaYXKFYSdWV3t6XVFH417KNVI6hIAd1KGHzw4ps3HoIfkHCGE0M91c457wT+BDOW+vlKLeVw6/D5xX2DGPRqQnCOEEPp5hDkHkF441XC53xCbnEPodxRs4Iz4XHrbSc4RQgj9PMKcQ38IWBr/oji3NO6D5BxCf4X58O//r819kZwjhBD6eYQ5B/hfJ7gsA/fHJC4dfgHqTztsQFLAEEL42nicOceExKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf3ZwjhBBCCOGyLHlGfue4KnHpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczTx6F366dNfr1///PTpt0t7H8SeP/9e9dNnXZbHehw4Fn8ujel5//53jp5nYGmfxX09Qv2wU7aJ05Z2CA+QuXKOjx//5Pp49uy7Dx/+WLp2+Pz575cvf3zy5BsKFSYuA7NyPZfiK7sC17169RPOWcYasQ1Le5+ac5w+67IMx8Ftjt+40OXDN29+wYf0LMMPh68w57ivR6if5BzhETBXzsGNqXv/izkH8UAyfGrWvQTa07mSSxUp3779Vdsn93rx4gd67iUJI9qdcfVjcH/AqMfx7t1vGODMFU/So+dQAg8XTuSLr9Ij4LwHL4TQz1w5B/AVk+vj+KJktMZUmkwh7i7tKbmGS+Wr9fceJWF3/Pp4BrJnaZzM/eYcenhIONQ0PGD9Vl2cU34yfASc9+CFEPp5kDnHGqYwcWlMycVdSkrBrv1HigpZCEP9fxp4iDmHVt/Mzx7i31Yq2M/WknOEEObhMeQcnz//zZS9vyboD/MI8NX/Hv/UfXGXvn37K5vazLTkEPZLnWjKrvWzh/7yzXffGmJJUEhc1P/u3W9L780Xff+lHAfqbzdrENN0hOvVb7dT6rdt26MmOOdARvIU70tNZNS8FDoOjEH5Zt42gG3aJpZXb+AxbMNa/TmGQoVR/dpP079CoYGJCOMxHMKonkbOETGa3rIcQlFTdXng+DS9BHUZ4KKjUdFZ2Nte1+ydHew9LZqijbAj6polJTJpWJEpSFq/tyb/+FAQpsksPutPensPXqXqlLD8X4c2PQneKTIyWKtQZPBwTKc/CaB+OhliFQ8dW+Ul1Dw4phCm5THkHHoVl8YKhnireT95dXWJ3Fb/Rbi4S+UoX0AD2iYV3VySlBO40biqJMZlR1PekKRvZJq67BitUyoIM6S/aiEm92oIee5BVqRQoajf9qgJurtV11rIqAkcbm1eCh0Hy7H0wcMjZBWfrrNT19HgEKvdETZwHRtHszcuSQcYpYzIa6IikxwO1ZPooSkj7b3N09QS3s7wKmlFHZZgYm2avbPbe1pkIbM0RUMSo1lNwmCaemj5lMFVIYVVFLbpxC3UqaAH/YzKRQcPXoV1pVOSzPJ2jj2JDSxNP3X5TWbomOxSmUSFHu2FnrqdzScBaNpdUqKn4sAqLyHvAf3olBLvK4TJefA5B+8bN45uok3qW6pLkylqdnJfOQfo5lUdaFJU557SZQq6xxVFdLcORWIVXZ1Lo1zBwO3pIZmqOqztqU0J+0Cx8OBwz+ZWOYcC6tK4SYOYJb9Jg09BTT+9w8aHtQ4mrl3kiQdDUJfQ6tYJDDky4dW9KLV3dntPCzJV1bCXahLQ9K4HCxGj6deTCs2haC6Sew/egHQujX/PTisOQzQpqiuJqUVDg8Fqqq5de2tqbkpyC1GvTzXeswMPrBqWOHjFQpiWB5BzqMdl6f0X3jpdfHswxW/pcBF0cnGX6usXycHS/i8MnXKL0a8vWAMI2GkHML2K6aSWxg0o91e3pWvLntok0tTvdjb1sug4eHJY+otLIFO3qVioniEMDA/Y4BDqda2DiWsXeeLBENQltLp1glZR3sCoV99kfXZU9p6WasOwF+qDhV53sBAxmqqD9CyN/1KVgPQsjf8y6KxnNwzRtJ3026rKYHBdV9baKjU3JWtdKMVX/cCqYQmx+YqFMC0PO+dgyF+89uB9JvryrYLrhpfz0fzOwY7wRv1+abiGGHI6cnCL0V+/L5oqcwDT6w2ok1KdcI5tKMeY2g9re2oTJM8Gmf7F8z0PHwdGstbxI4HAkNvRo42fHmmAevXqwcS1izzxYAjqElrdOgWjemb0UqhzYO/sqJzytAx7qSYBTe96sBAxmqrDoKdSlUA1cmDQCTT1UA1DNG3noN8MBtd1Za1nDcZXSdXrI1dHD6waljh4xUKYlgeQc+zBxVEDEu/e5h2qVEOhhbf3+EeR63ENl+rr0Toqs82aWh3cYogx5D/q40AFV5xJf3UpPlSlwnSrgnrxMeQ4PVyIa3tqE7Cc6UoQl65L4+NQfrYZSrFf2+fhodifdDKFidRPjzRAvbrrYKJOVnVglieuvTfodFOrW6fQQvh280DF3tnRT339tLAi/lEnDHt5/u8/RhEMedeDhYh5LZCfWVSuBiS1Op1VZzVyYNCp49axDkM0rVPXBWvp0PnUE6LpNriuq117a2puSvLCUrcbAeV4SfUDq4Yl9o4phJmZLufQbetbZg+9Y7XUW6/C3fpFbQ1cyaXcVlw9vhzJqLih6Kmplf447ZBJ0xccEwcf6pbkUkZJHdqMyjoFPlHOilpIB0FFUU0m0USnrFrbU5vCmpf2panHwdZkrZ1GhU4/Noo09GAkhYrDgIZ89SuceKIeZm2NT+r2vAKqJ0qPJ2r7mMEszkghUIuuvWedwxIKUehEg6Ks0HE4HK5hdPPs9p4WGS//0JSY9aMBSYZQon05WA4vu7amupBALdqIHw/UYpgm6sEbkP2YRJ25SNrnmrXpSe2oFmX2cqm00SPlrItmTbHygycBWAgnyEV8uq6hQXKwyktQ33vFQpiWuXIOXhsX3qKld8X6JqL4VRwYxCh7klflei713Ufh+mN3vrDAQxSarqsJXKDMosmnr0jwVc6F6HCyhntf2QnrUucS1O3p6IL+elcO9gxNw3L0KMBcg+E4sBnLZYb2O9zdbMHesIeZpSkU9qstu1m3ViXpH5rDRDSjX9P5VESRSepUQcz1oYmYlGAzBiteGvayGZ6N7FmfHew9LSyBvCQ1RY8BYLam6ClCDP2cbN01wt7aYBsKpZm91BWZ7hWp+8EbkFpk+ETeGzn2JLAj7xT96gSp0vbpRw+VeqB0UmqzriUj8QPe8L5s+YFVwxKMahWUrI8phGmZK+e4BrzbflddhojSwGNyaQPcofoOdyW+5uMgMhGllsYVUHR0HL1fFMWXRgjhvnnkOQffJ/SdoELP9b5A75Gc43T0Bb1+qb04X+1xkG3zzRgPL+0rkJwjhLDHI885+K7MpVOvPyLZ8FNzD8k5TsF/4ODUlq7r8BUeh37Jp6yz8MvC+8UqV00ZT0d/EbtqjhVCOJ1HnnPwrc5/N6UQye7rKkzOcQr6YzmZx7WDxFd4HPq3Hdf+k7/+kYHKtZObL6IfOVSWrhDCvfLIc455iEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqchwhhNBPco4m4tKpyHGEEEI/yTmaiEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KjiOEEII/Sy3cHKOqxKXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhO4fPnv9++/fXZs+8+fPhj6TqL169/fv78+6Vxr3z8+OeLFz88efINm3r37reldx82/vLlj0xZ2lcD/+ClpXE3LnVq1+CC2zybT5/+woanT79d2g+f9Y5m8PMeyTmaiEunYvM4uKOJRoSlpf3V8+bNL1xk+ORx5BwEY7bD+VIhjTjFJG3/YeUclzq1azBDLCSJxDmUpf3wWe8oOUeIS+di8zhevfqJ9/aC7+r7978TAJbGwwT78clto9ecG+fb/xnZA9tvyDkuyxmndqUjmyHXXMOB1gj9CODWeig7Ss7RRFw6Fevj+PTpr2fPvqPUnyjvCEnM15lzzLlxIk1yjj2ucWS8U3MGwseXc+jEl8bcJOdoIi6divVx8NLyPZjCq3vKX/q/CEpQNWHovRVnRK9pN56cY49rHNnnz38/f/49apf2TCTnuEeSczQRl07F+jiePfuOW5LCq/vy5Y9Lb+H9+991h/qfH3Kn06TostZrT6EfYdXdgwDK+TbpfyKw9w9HvBCSg2apctOxkClYpU6WUCfUFdkUzWXgRqem8Ml0evwv0TCMTv0qrrXYr65pC4OU06l+7XG98fU/cGOiehBgFStEGIUsREUe8AZBe5R5e3//OtAse1zUX0Gt/i7O9KqfHh0Wq1P3s7HpLtC/30SSTx0fYJj6MUmzKOuNqwl7xgzYUYihwed7yqnxSSca+KTpQo/tQYMM0JAsZFRN7w78OGEPxtMjw1Q80duUYSr0S4Oa1MEeoNStmepSSXqbViXNXutm3j+oR3V5iSnaLIUKyrVrmnYdqJ9OhuoD5oeBio2hrlH7XP2yqtqPAcz9f/6f/1cyFMnwqWZ1tcFFcjIrasvqZ5b9DF6dT9aSZtjzMDJY5X51AktgJCuyr2oPdclrL0vvPsk5mohLp2I4Dm4Zv116D31fCN4l3je9rhLQxUo/db+B6KFZ74v6cjJRQyjn1eUVVX8FhVxeev/rjy5MxACmMMR0KozezFh+wVazTgFW0W2CtfRjgPpZQjK+j1DiCwgbGGU5BLCfHilBRpc1FYbolD0UKt7OsHGrVRNQIoVeXVcVK1L31uRb74VR+RzNvk8H9jQLRvcmsiP0Vx+qDnsm7blLlzJ16cHV6tfumMUo5mGJPaYh23ZgTEWPhJ4o1VlaQwenhio9BjQxwNMR8JHJHkZxOEqQRw891cIqzx61a8SYxXT1a13VQWqtRM6sB+QnH1VyFHVtDTNuRP4P7ZHiE6/bRBV17Q70MKgONkzKpUTCOlamaztI+piAppeTTtmvWRSsYoi51WYqKNEsKlKIpJZmLfxMnc/1cTN38/Q1RUNYjv+ZqCGptZ83T5z6pofpsQF8UtfTznLeAhPr0UuAfjlEOg9IztFEXDoVw3HwOvlV0VXol0og4ODnC4I6r2sVVlNv9TAktUORZEV3Ry2+O7QuAvRodUEdMdtPXYtisG43wY2gq4fbwcpdNAXN1BG4mfEP9NNjOzWXi4Y62nRPgcRUHzYOUqu6/FAvJoy0nQx5v1D1ULcZXrdyrBnQXJVXUGid7BEn+6I/MEn7srvkHD8ngE6bNHiyegyoe5UDYyr0WwxY16sPa9VTY4iDk80IS2Z9ZDTRvzRuoGfTD+yOut2OTp5S1eUf1cWghCW8KCbZdZiK5FA0VBm2KUukcBhSU3Wohg17V3Nz4vEDNmyWpne696aojlo1BbOsk7XqA1xBrJ4+9bo6da/OKusT3/Pw3mXCLCxRP5/q1HM1FA0dkJyjibh0Kupx6JYZyvCq0zNcDUJz/Zqpqbd6GKLiW+AAT9+EKwMBpQ4Duggw24vyOYQNIcOWxn/BwmEIJYNJyNSN4BbsQcYTh41DVSuFqgtdf6pTqcqrHvZCk09HpoFjzTBYXqFfIXnNgUn0V/3aePWVopR6ZJ5HB2upe5UDYypMsSWgAKCeYS1Ap/TLJH2vdWiR5VUbTdsjhh7La65C2gDyDC2NGwYlNUGhbiXIVGP2WG+Tx0P6hyE1VYdq2LB3NTcnDkqgPmDDZmnKErN+UwYjhQzQQ46ADRtApg4NtlH36psnzuieZlhfJvSggSZbsMEyVfXTSc7RRFw6FfU46lsk9ALzri7tm3e4fqsweuv89qopbcMQFV7azau5UqesYUhfaAYZ7j4uCL4NczV4lE/qvmVMNXJguDdBSqow17pcwVciFqWOoyQmgWHjUNVKsvqhzqVSb+qqhynUdQ9iw9qTx5oBzVV5hX40L43/cmAS/VW/Nl4fm+pqGWNPDrZR9yoHxlSYMqQm9Mi2YS3wqQH9Dn6KbbLT+wKaddcw9FheczcTwcE/MCjhsDy37gWZYfVN1ttklrY5DKmpOlTDhr2ruTlR9b0HrOqEuoW9N0X1ar9goh4APtfvr2Ai05fGaoPUvTqwxHDi1byBzcsEaLIFZR5y8uCrE0nO0URcOhU+Dl6k9f2ul813NOhN80/cCOiK1KXp17K+hKp7iFedJle//yzCkOsGY7SQrjY+bQYaVOcTGd/yCNP0VehF1c+KWKshbKau3bEjR0dM1da4hhhSp0AVPb5WNFdLo8FxQmKqDxuHqlZ+sCeB7WCk6gzVq7DqsR+0L5tkjjXDwT2rGxl5u5EeVQ5MqvsCOccTQSZJ5+DJ6jGg7lUOjKnwqFAso9V1psNa9dQYoqlOnKNF10dGc/CVhYXl9Ws8D4OXwwatNfgH1mrZJrtgip9GoBNJPmUqbHpg2CauoKml0VaHJKk6VMOGvau5OfH4ARs2S9M73XtTBvuNbGDLm7sW6KyeHDZI3aMMrU98z8N6ufxQUWc6FUySYxnSXOrMpbJ5kxyQnKOJuHQqdBx6CX0dVOjndfL7o1fRhVvSNwVNva706G1kVO8ndZRzKaspnS6I/TP/v+iurEVz+fTtBlwcDOlV13XDKlwHiFGnhyGaLCElFOq+hrDK/Sq6emShZIQUIo82CgLsUUP0a+MsLXtQoixKU4aNM/2faTdNhyg+XUcAMW9TTZ8OdR0HaqlroYE9zSDjKTajIp0u+EpX7bFJ9NNUXcixslNPl/R4yLezmjJmWGXPmAE9KhwH0ylUfL4Hp4YqmjruGtUkryOTPdYmaGIJQ8xFCQK4lykMoYSmCp0So19i1CUmtd6m4IDWnSyBHilUsf0V6a8esB6p1UGwIz2fGKaNI0ZTRsqNshDkus1jAibuPWBVp5o2hv7NN0XKraEisc0hob3zyYqo0upskCF6qHt1ZKgPJ77nYalFIUrkCnrwRt0sXqVOBbSFWrTQAck5mohLp0LH4fdkuF7dX4d403il6eHTVxLwZvIGUng5eScZ1a3NEK8x8r7O6PTtTIUXW/0DTPdC6KQHtZqlpu4F9/CSSx5TqXO/0JRyml5RV/M/C9yAVbp0kNd2dM1RmC4ZwahvNBkgZAZK8Awy1L3TunGrpWgUMxDw6r5YLcYUb1lNRlmOIlfjIk0Z2NNctVnhADLaJtO9zTplMImi+uAu5uo4+FTMU6eEKejxXDVdt2Gbxqzx0SCGt+v5Hpwaz4YM4NNT6pFRkU7FJ8Es7UsPkgxTgKHpxwmdfrCp0Mks9UitZCQgEPCTY5jirWnFZaAgr/rEsbaKoZNOlOMKJFmUCv3au0p1PjJS6OYgyVz0bz5gVZKm62pKLbPqm+K1sNB6DGL0L40d0CBLpI3tS4/UUuRnhnCmLOTTLtr08N5lgmZMQowh9UgJ+OgRloePSc7RRFw6FTmOEB46CtvrgP0IIJA7YX1kJOdoIi6dihxHCA+dx5pzfLz5fWjzp51HQHKOJuLSqchxhPDQ0V9PTvk9/6GgP1JQSKeWrkdHco4m4tKpyHGE8KDRjxwqj+anjuc3/0aVXGppP0aSczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVHEcIIYR+lls4OcdViUunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCqmPY4PH/549eqnFy9+WNr7nC55K16//vn58++Xxlm8e/cbVr1588vS/i/v3//+9Om3nz79tbS/xMePf6LtyZNvnj37Ds1L77ncfXchhLuQnKOJuHQqdBwKZi5EcY3eI8RjLDklkzhd8lbcMSrjQxl2kZzj8+e/ESbtoMJO754uJOcI4X5JztFEXDoVPg6CHwHy1auf1PwiBK1rpyanZxKEz4vnHHcH/xzkHLfi7dtf77jBhvMKIZxOco4m4tKp+M9zf5sA+ezZd/PkHIg97pzj7htsOK8Qwukk52giLp2K83KOV69+Qjg5xzHz5Bw95xVCOJ3kHE3EpVOxl3N8+vTX69c/6x8cvHz5I0N8UdY/PqCfpsvnz3+/ffsro+/f/05c9L9RQJX+QQOfCNxo3YaJTJe2+scdmihkrvQwxFrL2M2/0NQs/d2hhmSC6/Pn3zPERM+ynYxqC9Q/fvwTa5mrpiwHKtq+mkxBD2LWXJfbsx9hejZzjmoMzQP9UlKL+lGrRfnEAHUCdWmgX//UdDgveobdAT06ZQoV3KL+A8NAR0w/0ze3GULYIzlHE3HpVOzlHI5A9BAgCSqK3xqlkyHikOoM0SSMEauo80m0o0ehS6rQcDN1hH5GlZTwSd3/UQZ1tGkVKbQBND2k4F2DtIdUJyhSt51UWJRNMYuyuUFvX01NRFh2Etdpys4D+1mdJvrVrNgY2XmgX7C7GuxxtUaxHJsRlnuZiCrp1BZ0BCzntTxEURMlzNLS6MFdNKXwwDA0089cCgo3txlC2CM5RxNx6VTs5RxAkHNYghr2hhimJgFJTSBEEZBUV+i18AChi1FFOKBuG6gPgZYeBTliYQ3JrGVJQqZTB0CMWRLeNFt1qBsE6nWUeh2lKTsP7NfG3RwYjKG+qV9U29g+o0ORMH6wWzAML23mHFB3h2N9WMBeGLIPqW8ahjZmaeN8VmtDCF8kOUcTcelUXDDnqCFNEPAIXfqurFHpVKmRTEGLGEa/bRhk0EAPn64sA/+1rWoARWj1DHaqqTpUJUC9jlKvo9YpNu2XnVWsotVtzLH+apvUqj5Af838zLAW1N1V5YK8zT2I1VGaMowt62Rfvvyxag4hnEJyjibi0qm4Us5BpJc8X7v1g7xGpVPF2vQ9++3bXwlj9NuGKgPSgwyqqNTltJbqDKFQdWGdm2arDlUJUK+j1OuodcKe/bLTzYHBmAP9UG1bb9/QX3/jMcNaUHdHXX9+MnU5xFwHmjaM/Tqn3Fw3hLBHco4m4tKpuFLOwXdfh7GDGAmEakbJUdSkbhuo12hHVCO0U9GfMwZTLYkMxQqVB+jb/6bZqkNVAtTrKPU6SlMGHNivjVc7K4Mx1Df1i2qbdkSk908aKMEMKgr/qgOSSr+GtaDuDsdS119hBA503sbQpmFo099x2Ls03IyHEE4iOUcTcelU+DgUyeq3VZIGehxNaQ5pBDFPX+6JTzSHkKbAX0cdIysKhwQ8hPVvL+iRpLIHqWWIgOq4iH6ainl8IsZEGc9c1VGocOiQKUtshiLl5gahbp9P6h5Vs4bzTftliYP3QDXmQL+aso2KejS3FvxMvxIgF3tvOC966u7owZn0WAlNDcmSTcPQiZj0a8qNSAjhJJJzNBGXToWOQ996XQgktQcB19Uk9hCHFPUVdCmOcEB4Y5RO4hPxmDoKFcYGiHPKGBCgjlqayi2QJy2QnpflP+AEDdEvGxilqZAJrK6YyigGaF3bSRk2SNN1CsJ726e/CsvmTfurGEv/Y1ZhMMb1tf7BNnqkgX3JM6yoxEUQ/mUPn+6v50UTJVYoAQzGh+qhYk9abNMw9OsUfGQhhBNJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVHAcIYQQ+llu4eQcVyUunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqchwhhNBPco4m4tKpmOo4Pn/+++3bX589++7Dhz/U8+nTX0+ffvv+/e9qNrC24S68fv3z8+ffL43Hzm0PC1e/evXTkyffMAtHLb3nwrrowYalfX2wWQ/J3Z9S9OCKFy9+WNqnsX5W+51wW87b6d3BJ6yLc5b2CfDmHjyWX3y1Efj48c+lsUVyjibi0qkYjsNvJpGAu+zNm18UGJbhK8NyWtp36N1v89uytuEufPFiekzc9rAIPIRMKniJiXeMlJ3hlpeCY+VRUfPuT6keudtG4vWzOn/Ocd5O787Llz+yLmVpn8Adcw4SDjb77t1vS3tFco4m4tKpqMfB68E7ycup9JyLlR7dERJogGuU5S4S7wVXw221cXFf1ob7ghO8+OV+hj834Rm743PFMTnqN8M7omzpguCNMw7rIT6r5+307rDoXR65M558HnK+ue392pGco4m4dCp8HLxOvJBcpmqau8eGW3HxnOOMv5LIFRe04b4gZbz45X6pvzrpoJfGWbx69dO95BxsHycsjcuBN844rIf4rJ6307tzx5zjvCf/4B1MztFEXDoVPg69kJu/yrb9bQUum3Ng+RnaHuI9voZk8enTby97uZ/nz03umHPoN7l7yTlw6cV/5AC2c8ZhPcRn9byd3h1dcUvjltzlyd+bmJyjibh0KnQcpBq8GKf8ywNeHsQQJp7xHn7+/Lf6lc4TA/TnGP0hk9HXr3+WsP/ajQYmIowAXx0YrXqGnMNq1QTqmoUZ/tGS6boUKP46oqVdJMkU/2W3rktF/Uzf+71atnlIVxhFozZV66IEr1Jn7xLwxqnIh9Q1BMhrXxTE1GkNmM2oZql47mCGYCKzLIxVa1WIUfd0KshoOqz9vOnPSj0sL0fFjrX+qocif+IBbZBZUiJ8ZPSjkx4dkAvTOb7hX1PSIwMQQC1T1H9smE6BURbVWgNIasWlfcPpGwdvk34mLr0lEqOcOkUK+VSzbm3zWR2cwOfB8wZoln/Qxtyl979YCaaiGWG/NdRVrJaKetREv6bITnVCnQI2D2OsHOxVbQoBOUQghrDsR0yP6IG1IPNoqsKiOhcfGUqYRT+dVkWdUeRd6hTqIGMY4pOdMlf9AiX0L41Cco4m4tKp0HHwkvDC6AU7ADFeM71Rqvv91MvPq6VR3Ym8lrycesl5mf9R8e9V5WtIl6bfSd2wdQmavmtQqJsCnWjwO890mnSq32tVbcBEDOOTupRrXWahljoVydRZFd0+HmIKTSo2lZ2iAW1clNIjAZAAtulbsjauqMMU6urn0/3WgDA9aJBybxzo0d6XdoGJPtO1KjqZSD8VbluGfAp7fh78WbEHdFhejqa8yqj1g1QtjRtvsKh2UT2gidUzqrOclFMHKlrdtumiRyFFx8QS9B8bRl3Ri9HN1wGrmLs0brjVxrGBpoyUpJYD6l4RMSsELapZ6Nx7VpGXJWqqvvm8gYRZ3f6heEWjfpTIe1Ki7bD6waPIaWot62f0Ruo/O5X3ZLDq6HQdSZoa1atnJWxc/TKDdakjQNm0FliU5vpcfGTIY7N2pNVtJ7NoakXwFDXxMD1U5AGLCSyXeQPJOZqIS6fiVjmHLrul8e9VqJtFGnxnqel3T2+s6jCspStJ9eHdrmp5n6n70vHtALzwNqyuNWjTtTUUidVLQfvyrMqgsK4lU1lCTaFrbmmsNk4TDVQU8r0194M06B4XWkhuBzbu+gBidbm1KhzouYxK+MDPw/YHZNhguepg/aK6Dni0aNYiYXbnk8VyxDZzDqi2Kdh4C8D5+ogPDLMG8LqVwWxx+saxwQ7n0HHsZs4xKFRThtF58KxWJ0DVCVVntQrH1lkDgxLcQo/qMsw78qMohUPx0tSt8LwrRec7FA1R2bOWfteBpiU1VF8NqKoGx0LVxihXkKZjfBUDzV0aheQcTcSlU6HjUMzzC7YHMr4CQDeLenQjeFRNv3vDW0e9rqUbRMKS9MSqVvXhXqigZ/j+MWhjUVtYob/ao4U8qzIoVFN1zRr0o9YCQL0uNMgTI2kSUWr/oEHQqcCDN6js+WRYblMVc7klFfIlrI1s6tR+Nz0DgweG5WhWY6RqadyYuqmWKUMaJ9berrYNykHppuoHhskPfCrsrVlrhtM3Tj9PqeoDDFlsUKimtla1QR2C6gSoOqHqHPTUoYFBSX1bgaH1oyirbsY3qAqHdZnuHinxqJpal85qUqUqh2ot/dTVDzQtOQyJqooVrUfUKVqFDJIUp2a6QnOXRiE5RxNx6VT4OBTqNiONQWAIAPR88YKA4a2j7pcZJKx3dXi3q1rVN4MBORP288Lz8te1Bm0sWtc1Q78W8qzKoLCupVky1aDWAkC9LlTlcSxb4Es8fqj9gwahtXAFpX5NHBiWW6tiOouyNA5kVMJWLpnKsP2BwQPDctYvpGpp/NcVFaZg4dIorL1dbVO9Psx1uQPDmIKk3gUyj/XrUPWY0zdO/955MWSxQaGa2lrVBnUIZJ6bVSdUnTUYD7MGBiVa0ZFVzeFRVOcpCqmfcaXQSYDfvKyqctAsWUs/dfUDTUsOQ6KqWrtomMKQv/AM747mLo1Cco4m4tKp8HHoDtq8ELkU9NJyF1P8qis6MpG63u3NCwKGt466X2ZQuFV9eLerWv0Yw13jUZbW602nb6661qCN3dHk0zem/grLZ73CtKhnVepNDXUtzZKpZriYqNeNW55Ug7oNqHoGDYZ+nEZc9I/za4blBlXyp44PGJXwgZ8Hfw4MHhiWs34hVUvj35QXP8gJfOpR1D1O3c7Rka29XW3DWmnTEKABX6l+YJgWBZ3IeqfSbGPE6RvHqwzZMJ5DP7f0Wwz9VaH0y5jjZ7U6AapOqDqBzcpUnO/HYM2gpL6tgtHhUdTNgJ1Wi0nedVXIRIq3c+KVolOoKyKmelUO1VptVnWgaclhSFRVg2OhTmFUVwqfWOVZgtHBYyI5RxNx6VTU4+AO4i3iUvObTIVOXxxUEKCHO4KiO6sO+QLVpeCJ9NP0zULdIY3PejdJcljRahWBVJjl24qmQhEG6y7g5aeuewol3Hf0UJil6SpsgVkSQwMCKNQqKK9XjJCkbk/2qLWQZKJM9RUpuIDolJF8UnfkU1Nb042GwXTKdfTICdJwM+M/yJLhdhtglOnolFWDqroX1mIXyGvRPT9riv35j5aCPODDqntXk6I66GGzEs2tBT/Qj09qJ5bYwzRZCwFJDk8Oaw3PmOoaQnLTMPrlEK3Lp/oNBtNvVeL0jaOcIRc/YwjTtBjQ1CONgHyFMDulqaHNZ7U6YdCppo3EEtePYdbgSTtZyKThUZQlteisB6vkulOuFDW9NBpouuAB9VPfs1ZTWMVNm6Eh1cVgp/aIKj/5VRvPJE31cyI6OMOOdM8MJOdoIi6diuE4eLV0i1F4XXlVhmuXt04vG6NcB3rl9EKq8PpRapNXzk3dBVRQon7dpDe6l9BryUEtAizHoixND9NtmybSz42gu0lXFfIsRL+XYIrt102nfmZhidRqj54yoMsUYcS0Oyo2lX6ZCnXjNF2nv26NJreVV6fO6jQx1RpoSmflwEjBqHSyzU1V6qQHe+RYKdzz89qfZjgsL0dh1PV1Uz2ATjmBT/sQ0Owjq/0cH506aPqlioI8PZiKgLbAdHXCsWHooTBrc48CDYN51kD/sX7gEfU2eXLUaRmmq4fVZQY6WQJhevS47j2rSFpPtQqxoYlwtdP90j/AEEtIXmYsAwXbUPEjxOjBTrUFehBmimwYvFq3Rh0BxHxTUfEjSnPT2rpfibl4CHkJQx2lyXKo9VMxaMMkv618Dm5klrdfSc7RRFw6FfdyHH6Tw9lwr3GXLY3QiDKApfFgIXY6arqQDy3DBfqP39apHsUvWtsMfiZZWRr/JTlHE3HpVCTneKDwJV5f8UM/OJ+yNB4mfDUfvo6TS61/q4Avvq1TPYpT3S14mPTUv8EMJOdoIi6div7j4D3kXtjL/cMxfBPFexS+WQ4xI7SB53mAH27aob/vvH//ux8h4qL+ZjFw8LZO+CgeWNsPLsWSzTROJOdoIi6div7j0D1FyU8dZ0Cc0K269+UptEGQ/vDvPxN5WBCbX9/8Bx16E3mcNhMOkABl/bZO+CgeWNsPKenx45Gco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqchwhhNBPco4m4tKpyHGEEEI/yTmaiEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0M9uzhFCCCGEcFmWPCO/c1yVuHQqchwhhNBPco4m4tKpyHGEEEI/yTmaiEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqchxhBBCP8k5mnj0Lv306a/Xr39++vTbpb0PYs+ff6/66bMuy/0ex/v3v7Nl9r60T+Pdu99evPjhzZtflvY9wdlxZEvjXCbZSwPnnXUIj5UHkHMoJj158g2XHS/w0vvQuJ5LP3z44+XLH/EP5dmz7169+unz57+XsUZsw9Lep+Ycp8+6LDoOwp5WV8GTdPJZO68RF8+IQ1ilt+AR5Bzz7KWB5BwhVGbPObiV+EpEhZdW8UmB4cFxJZeSYXCjvX37q/KMjx//JI7SQ0UCnRCKOKClcTIK/EujCx8HjmL1dRAlstLfk72xCk5YGvsoGXoccZotP5q9hBBOZ/acg2i61G7uKaIpmcfSflBcw6Vc2Vzc699+iJf38tVK9iyNk7nfnAM2g1+nVfpDw9LY5zHlHPCY9hJCOJHZc44BruZTbucJubhLSSm4tf1HigpZCEOvXv20tLtIznEGHz/+SYKYnCOE8DXwwHIOQmz95WOAK4zrm7vs5csfe34VP52LuxQ/7N3a+uEaV1AnNdE/iPEfp549+67+BEKCor8j0K8/Ywliof+xxcG/EUFM0xHGGCrqR55Zmo5m/0XM9qgJju6KqSrel5oXTzTPyDkwTzvF+OoQ75RPnKmd+t9IarMUL4E8Zyef4A2GmKsiGVyq1SlUfFjyz9pUwdLo1CwsWXr/NU+rDO+Fj55P6ozSiX4p0UZsyc2Mf2xAG51q1m0igxI6D54ce+NgLweu85AcOGioO0UMM+iUGTJYi3qWH0UmIiAx6ohJuWYZ+jcfgAOrkPFZq2fvmEL4SnhIOYcuaL/qA7znjHLRIMDLrLe6Xkn3y8VdytYONqjtU/HtjySekQ992XED0tSFKEnd1IjRVLRjtE6pIMwQtyp138gaQp67lRUpVCjqtz1qgq571bUWMmoCF3ptXooh59gri8S/hslRqrNZDbF9WYi7FF0oms7W5E+FZPZCXQ8qTWkDSaoOKJFC5jJkz0vt5omzNEM6CD6pay3ATjRwCtJmZyJQd8SQbZC1No/pNFWX5ZJEwE0MYCGWPnhyqCDDEMbsPb2yRDoH13k5lMg2DWktYF31yxg9cqwlbTcii6O0LvLUKbwF9g+SciOdNO1GrS79qrOE60huWjWctVbfPKYQvhIeUs7BHaEvUptwWfhm0UWj93wS7ivnANziOlRHcS/71uPO5X6sF/1QJFZBjyMK1ODEYXlIpqoOa3tqU8IOJFjo+gUZco61GweriCh1pziNUbmOuWyWR079eur4HNSyEbtde/TzSd1DwCn4UOj30FqnUby0oyyGHoVewRYwlQrW1lWgLjSYp6bqQH0wiadFTdh7ciRpCxV9N/ey3qZdNwypySd1pQhD0RAVGww0rYF+mqoDzT3JgwfgwCqg3829Ywrh6+HB5By83vp+sMfBfTEDF3epvifV677CkIPNwcVK/2Yah8Ap3hucrOt1adyAcn+bXLq27KlNhUPd79zUNvWy3DbnGGSU1KpH0U42O5wMcQgUjFWXoxyWqA/bRD8PPHGuDq11DrA6o5y7xfjU1/EBqbIBwCpeaDBPTdWB+oFJDNWmGZTAMNGsddp1w5CaspNOWzWATB2qGuiXZkFzT7LWoT4AB1YB/bUJ62MK4evhYeQcvLH1S8Ymuvr1bq/f83vn4i7VN8X6LdbIFU5HDi5W+jcdO1y+ezC9Xppyu+p8pcM2lGNM7Ye1PbUJkmeDTK/fxS/IGTnHkN7VWTxpTq02v/sCdR+WNujnk3r1NhqQZDl8SL+H1joryDOLTFQPhsS0ED2SMVJlA6AuNJinpupA/cCkqqcyKIFholnrpC7XDUNqyk46SftIBTRUQaaaVDXQT1N1GIyvktT3HoADq4D+2tw8phC+Hh5AzsHNW992buS9OESI0iXCW02oW3rn4BouxS1sdu0NnFDv34OLFTGG/AMS96BcjSfp59PhSr/JDzDdqkDXq+oM+dRqP6ztqU3AcqazIp9L16W5bc7BE0WxSxUw9IwxV17i8/nz7+WQIQ5B/XFeDnEcom436ud3P730e2it0+hHL5tnMfWztM+RQ6EuVfXJqQspZ7V5slZ1oH5g0t6TI0usE4aJZq3TrhuG1JRO9kIdSRyoUcRU96GIqoF+mqpDdQJUyYMH4MAqoN/NvWMK4eth9pyDt1pxsRZfZxXe55qazMaVXMpdjH/Yuy4yfTOmxzcvcOfiNN90NCmq6xJ04VbV5YiHB7c7XlZ0n/KJclbUQihhiIqCjUyiiU7HAJrVntoU1ry0L42PA5NYaL27wSqFYcTooVBxcMJIhPVMsmXtWoHH/fgZf/q5VbJYEwskUYsqTUSefgRwJqOSlA2bD7ncxV5QouhLD/I00UBTRdo0hRUxycdN00PVBrTRr7mIoZA6wpKUSfWYkNl8cphIPxO1ogymR6tUDlw3eEBNPtVkCk0XPYeA/dQxACVeV0o0hSFJIuataafDWpsPwLFV9Lu5d0ySDOFrYOqcQ2/vUHwpDOhmrIUe3yb3zvVc6qhA4dLkjqu7rm6h6bqawJ3OLJp81uuPm1E3Mhe0rtpl4L9waSKAGOtSJ+Kug4rOUZfyYM/QNCxHjyLNNdBx1NUpslwxz4WN3Mz452m0Q6qTEcBXUsWn+qUEb8i3TETG8vSoaEWFH8+VKiYyykIsh0C1yiYZHKWFmEud5WhqRZqYoYn1HKnUhahTNASsqyF2zXIM6dmQHgo9NgmxatLek2MvyTbN8qiR2rXrBg9QahMBVHmnVDQLtBadMgarkMctMkYFMdcpdS27ZfMBOLaqNpE8OKYQvhKmzjluhS7uoay/Rd0XD9Gl9wj3O2FjaVyBax+HQhEhZ2lPD1HQwfV+eXCuCyGczuPJObikhu9MXF4kIkvjvknOcTqcI18B9cX6SiTnGEjOEUJo4JHkHPoDAVHKacfHj39OdW0l5zgF/zZ+7fh37ePgUWQX+nPSg4DXhzxvadwrD851IYTTeSQ5B6kGl5T+Vkrh9pzte1JyjlPQPyMg8xh+sro4Vz0OfVNXeRDf120tZem6Jx6c60IIt+KR5BzzE5dORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FRxHCCGEfpZbODnHVYlLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqpjqOz5//fvv212fPvvvw4Q/1fPr019On375//7uaDaxt+CLv3v32/Pn3b978srT/y+vXPzO6NBrBqhcvftiz6jw4CDzz5Mk37Ojjxz+X3hNgIufIaS7tRm77CPEAvHr1E3tkFme39J7LfZ1+mJ/kHE3EpVMxHAcXNBcuty13LtGFiKUreBm+Miynpe8x51jbcAxikp8q5/iiVWeATh4JngeyDSq3iscPKOcgUSPppMIG725zco6wR3KOJuLSqajHwTdjotTLlz/qKyzRhR6FLgk0QIw8Pd6fApf+bbURn25lA5KXje4XgeO7rFU8GFUb+gnPS2MFPpzNIafAk3/Hp/2Bbjz0k5yjibh0KnwcCpzEFTXN3W/hW8F9zXIXzDlu9VcSIVecPkvyE0aay1o1aNPfbpbGilevfnqIoVeP39I4iwe68dBPco4m4tKp8HEQP7htN39JbvvbCujSv1TOgeVnaEvOsUnVRib69Om3ezmHfjB7iKFXj9/SuD0Pd+Ohn+QcTcSlU6HjINXgrjzlD8/EV8QQJuQQ0T9//lv9+tbLbas/x1CoMPr69c8S9h/U0cBEhBHQP0isenTpO95brZpAXbMwQ38DAqYrvaD4hw0t7SJJprx8+aN66rpU1M/0g7+tMF3JGYahX51I0iMjVVehjmMRY/uW1N6pyI3UNbQGhUxEhk/9CwOwQ/QPXRmtzgEtR6lWDdhdfLJZJNWPtXYOFbsXJepUYV0ZpjIsIe+5oJzlhn+WyxQ04AFW9PR1p1xNkYDq1WOs5adxMMPUR8jH4Z1iFXVJSr+LrN1bwg8S/XoS1hv3cpoCuEI9CKCWKeo/Ngwx+ZxFtVZ4BCTnaCIunQodB/cj19xB/BOIcfHpLlade9N1NBDDNKp7k/uRe5N7Fs1cmv+o+Pdmp6kLVzc1EzXKtU6zLkHTdz0KFZPQqVtY/UynSaf6vVbVBrrQdZVLudZlFmqpU5FMnVVhSOGfUWTUqbqjGjKOJVJlSW0H86REeycoarRCJ0OK+lKCZtlMHWtlHg7R0M2kf/xg/2jvdl2F1dFJBUmMkSqmoFyG0Y8emtYMgzaaew9MdQhQkdlaiE35sDBDYpudgBlMVJ0hml4U77F9OqljNmJrT9pjUujjoMlEdseonz2g38vB3hKaKF+pX/Vh415OTcB4PWYUKgzpUTk2jLqeBEa/+JKGh0Jyjibi0qm4Vc7BjV8vaMVF3cLDbasmn2oOV/mwli5f1SXpiVUtFzF1R0HW5S5WnSvbhtW1Bm2K0EORmNMU0L48q4LZMga8oo0kMCCgEGXo0SqCet27Ji6NAjHMJkm/7PFae0P2j9y1qZxOPCY72aym45zqBE2vxz1oo1k3UhmMBOr02E4Wkp18SmyzEwbv0fSiSkdq2bRnMOZAIcjOpbG/BG6xZ3AjYps5B9TllGJqj4It2+cHhtEv10E9kfCgSc7RRFw6FToOgiX3mu+4PZCp9ym3rXuG21ZNX5TDVU69rqW7WMKS9MSqVvUholfQM3yzHLSxqC2s1PsdtJBnVZS1ECfQY0skz9LkQDWiCDTbHqBe16K5aZLgXIgxqEVM9mgtT6mmarPqF3vK5XB9k7bBgxOg/qgAgzaag7wZjATZJjtZUTvCY+rZ6wSWoHNp/NdIKzxmMOZAIcjOpbG/BFN4EpZGYVgL6nKDctDjpPqBYUp9+FR+Hx4HyTmaiEunwsdBHOVeO4jogMBw1dKjG3a4bdX0fb2+yn2fgoQV/CTpiVWt6pvXrn6ZJ4ISTetag7Z6j1eGfi3kWQMYoBhAjNQv3pJXzsGQxAyabQ9Qr2vR1O4GOAhZxXI1J9NanlJNrRsXe8qBKc7P5FLWGoyXAUtjpY1mHa0MRoJsk53AWTuX8hf3zU6WoKk6VJOGJfYYjDlQCLJzaewvwRT/PlFZb7wuJ+X1FavLHRjGFCT1hnJGxy9peCgk52giLp0KH4cCm+/6CnmGEgJuPYqvPDqZwkTqw22rpmNMvVuBuu9TQL9vcEl6YlWrH2OISR5lacVLOp0M1bUGbeyOJp/aDhB39YkG70uLelbF/mGUKTJM8tSxkM7Bh0MsoV73rolLo4BJzgCqPV5rPaR/WKC62FNOpzzAJ6vIHjlHWZTgUGqKOWijWTdSGYwE6vTINj51ajhci+51Aga4DqzoRRWD2bUOThM1VBmMYfqeQpCdS2N/CaVr1NWvHj7XG6/LsUFpUxPQ4FM+MMz7Wh9xeLgk52giLp2Kehxcbdxo3J4OPFToVFYBzku4anX/+lrUkEOUrldPVOTwBU3dqQOf1AfJYUWr1V2vwiwnQDR16WOw7m6iKXXFAJRwWdNDYZamq+g2lxgaEEChVkH5+nJHubePgOJHNZKND2kHQYVR2ckndYcZNb27Cgtpd5gkn2AMCw0OUZNP6gizNMpltsInPTXICYYQQzN1NivXyTnuZxZNma1RtNV9YSHCCNQQa2QkR6BMQluQnZiHZhmpVfY6QbtADwvRryRAT532XovWGhg8hs00vS+aFNWBDTIqD8DeEthTO7HKTqBZN75eztusW9bQIGnD6Nchal0+1R8eNMk5mohLp2I4Dm5ARVwKFyJX8HDBcQvrcmSUu1VXJLM0hcLlqzjhppIAFd2wVFCifu5rh4o6EclBLQIsx6IsTQ/TbZsm0s/VXGMM8ixEv5dgiu1X9qB+ZjmeaY+bAYyFLKklBiOHZt07wq7TXyVp3qj/P1hF21QAoy7DPAXl2rWbzEJSK2IhdcVC79HQaUk+LUCnT5+KQ29diKK18A/1Or2i4C0X1ek6VjYiAdmJzGYnoNx2yub6TGKDzkI7VWflxONYN9UDe0ug2Q9S7a8bH5YDtoOATpbpKFH/sWHopzCLsvlYhodIco4m4tKpuJfj4Cblkl0aIYTw9ZGco4m4dCqSc4QQQj/JOZqIS6ei/zg+//ffNIQQwldIco4m4tKp6D8O/ZU6P3WEEL5mknM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FRxHCCGEfpZbODnHVYlLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQq7nIcnz///erVT0+efPP06bevX/+89J7L+/e/o+fTp7+W9v3x8eOfL178wL6ePfvu3bvflt7//e/Dhz/YL0NL+4HD8b19+yt7ZF9L1385/VgRe/78+6URQjiB5BxNxKVToeNQiHXZC0IDzCJoUSHk3D1dmCTnIBJjBmkHFTZYQyn9OOfR5Bxv3vyiHSXnCKGf5BxNxKVT4eMg2BN++B6v5hchKiO/NM5CQX1pTANZ1IFVjynnAPK8g5zjGsx56CH0k5yjibh0Kv7z3D/5hu++S+NLIHnHnOPdu98mDD+Y9PXkHGQbzTnHnIceQj/JOZqIS6fivnKOjx//fPr02+Qc90tzzjHtoYfQT3KOJuLSqdjLOT59+sv/SuPlyx8ZevbsO/9jC5q1KGgRUSRJefXqp8+f/5aw+/3vA9BDXZIUFkV4+PeM9MgABJ4///79+9/Vf2wYaxHS6OT7tNbaRGtprresAFyL+it0op/pMqxuEzbVHhsMbI0N0o+MZ6FW/z6XTwQ20wJvlkJFOu1JZmldir0HCNgM+qlsKqeTpWt+QI/trBv3BtXULxlsxN7QphBDhqaKOvmkE7WMeu8hfA0k52giLp2KvZzD2QM9RBcFDCKNRoF+RpfGTURhCp/UCU4W1kTCD3U+maI6UHdIU+yhx/GPIQU2ChWGFDiPDWNU+tGDjDoHmKggR10m1eyEdWugHUCY5WQkwZWml95Te2ywMgP6qWsWalVnIhXkidx2S4V+yZB82BJ7kiHmopntIHkz45+EAyORlCWybVO5lNgVyHjjqqNHQ96gh6gzKmF2R1NugaoTszEMSygowXL1h/A1kJyjibh0KvZyDiA2KJAImo4WgGQdVWgZCv2EN8dXBTzlBIDAWqEClb5/O1ABwcmB88AwKt6C161gA3MV1wVida2qbQ2SdVS7VtQ8UMsU6uqHugQOYagWDbELwjBqqaNWbhkgunvFqrN60k3X7UZgepUcsDGgTEV10MS6updAG3WfgppeouqkE2PkIj49JYSvgeQcTcSlU3GpnIOhzZhBv77ur6nhB6RQwWlQDoruqjNrWNp6JEYkQ4MC9sAQAmH4+0LVtgbJOmptx2qZQl39UJcYZhlNJ6sg0tfca4A9EviVuFhn9aSbqtelYW12peqkjh7VQTmWexDzEtLpoWEJ6tbJvvSjCNnVng0hPFaSczQRl07FBXOOOmrorF+sKzX8gBQq9qhek4a6HLMOlnYMJp59/Pjn0vsvCoFE9KW9CoqDtgEk66h/jzlWyxTq6oe6BP3V5xXm+s8W/kWhQie+Jc3SP+ywzupJN1WvYlCNXMNQtXPIHemx5Yh5Cen00LAE9WoAriOpUuZRf0cJ4dGTnKOJuHQqLpVz6E8J9Us58VKf6ncCoX6gf61QwYloSt1/hQE0kEmofmCY4xZ6iGR1OwLzmGsbQGvZvKptDZJ1lOWUUR2rZQp19UNdgukMsVNJ8qktYLk8yScbX5ukf8PhLKfqrJ50U3UsxC3e7JAQDDBU7aR4ovZbV/cS0mnPD0tUnXQql9KurSGEr4HkHE3EpVPh41AUccwG/VrgMEPTUR8UJBQXgYq+rbpIlUKjC3HL0YjYg0L0q0d/FnEYYwiFilV8uq4hJDcNQyfrMkRhrZq1GC2kIUV0m8QsabPyAYVeWUK8xCr/lHKglvqewfqlpBaFYeYiI/eSKNRsRmADwloOJVjF3uW9wZNqanXNQhua6aFC0zsaYMj5gey0b6l4COoGJcmiGlLTxtRDZ1EfKxuhLpkQvgaSczQRl06FjoNIQGBwIQzUHgRcXzfVA0RfxR6Ch4KT+tHmfodh0C8BLKQIJFUUBSEFNqbQw3R1wrFh6CG8EURpOuytQUwyfDovYQmrorCQ+ivVKgK2Ew6xqfbYYMAPnmX/UEG55spF6q9olFlYzmaxClVMlHIK/XV1+dD+YYg6vlWWs0YyS+Nmos+R5WzSsITrWFKN0dbqoSOMTvxJDyYNzgzhcZOco4m4dCpyHGEPJwohhIuTnKOJuHQqchxhD3IO/1oTQrgsyTmaiEunIscRKvp3OfrTCRX9g5IQwsVJztFEXDoVOY5QIdXQv/Z4/vz7/AOLEK5Hco4m4tKpyHGEEEI/yTmaiEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqchwhhNBPco4m4tKpyHGEEEI/uzlHCCGEEMJlWfKM/M5xVeLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52ji0bv006e/Xr/++enTb5f2Pog9f/696qfPuix5wvv5/PnvV69+evLkG46bQ196v3p4Fyb0xpxWnUK9XgY+fPjj5csfX7z4YWnfjQfxPL979xveePPml6V9fb745EyUc3z8+Cfm6gg5S050GfgS7PBSj9H1uJ5L9SLhN8qzZ9/dynUXxDYs7X3qpXD6rMui4+Cx0eoHSY+eScr8z9jk4MC3b3+lwgOAw0k31f+V88U7+l6Y06pTqNfLAE/dBV/k+Z9nQoO2nJxjAw6MYKljIzXDUyc+Gbj1QcSDK7kUp+ErHn3lGeRtuIIeKhLohEeNs1gaJ4PBZ8y6Iz4OHMXqFJ469VT0dFHuxZ/3wvv3v1/jhpKfl8Z9w4PKyS6NcMPFfcKNNMO1PJjBQ3gRq6Z6ngfqK6wb7LZv9FXPbpacgxu/fjvHR6dc9Ewhq+LL/QwP9zHXcKm8xBO2tP8Fn9xL3i17lsbJcHb9b289DrmLp2hpF/RLbL959whZ7G1vqFM479m4Epx1co6Bi/uEK32Ga3kwg4fwIlZN9TwP1Ff4vJzjqmc3S84xIE998R0gN5d3Zni4j7m4S0kpcNHmr4hkIQzx5C3tLs57Dzm7M2bdkXocGCDLeZaWrhvwMBfxzJfLxcEDbPa2N9QpzONG3gssSc5RubhP+Lp4+m/V12NtBtu8iFXTXgvDK3xGznHts5s05yBqsu2lsQPe5GsoFbxz4KDPc/xLn4u79O3bX/ceJras/VIncLJr6lT0jyeIo/UnEFxN4qL+GnR58vyPLXBg/RWqgpimI1zfQ7udUr9C2R41gbPTLL0eKt6Xmhd/AYacA2sxaUjgsB+H1E3B3r6QRA/CnAv9jNajoY5+OvnU34CFtdG/fjiZJVV86tcse4+J8puMxwxJDo7y4TLF9uyZqlTVxVs7HaZ4ufrMVLWUW2lGGFUYbOXDHtdeoqcuhLya1PGe6u6xNzRkP/vhp8JDTifYGGZp0bpNnSZ7px8ZzfKRWScTqWuKFaoJPjLEWGXpPZljCzGJITplocxY++TAqlMeJNTKCSrq5JNOlDBqDSdSbV43QU3MRrm8TeemGVSYhR9kMCdyo+B2WKcK69KJTj8z8jkrWkarI6mmphw/MDISj9F5IutXWCuyOoelher9g7z8QMESejaddjosV58cbVDKWUu7njTnwMTj3bIZNqZ3iYo3uYYhjg1JvKnXhqLNd3Jxl+qB3vOStknFrwGScgKPlB4v4DmgKW9I0s89TT6pM1qnVBBmSA8xYnKvhpDnaWZFChWK+m2PmsABuam1kFETeFVq81IMOQefunn9YGA2llCRn9UJm/uS2YjhAWmQNjmQLVCXY7V99cPBw4kGJlJhlEU1y97j4OhHJ3WU6Ah042iWmihBjDoCGjo2lR7qx6/eHtIsnaqzhIZgcOPpyFr8vLnHTS+pn7qMAQ2pLkuqnTTxoY6AVVBFp5ZTJ02pRZKCMZhBU8agnDpwOlKrWXo2fGSbL6BXVxOF9EiJJuqxOR2ttWch/ailoifH/dUnsLbqtg8SVA0sx9JooGDAGQ+YLLRyDBia1WkU9UM1A2hiyeazdCtkz9LYvzDpoY5nbqT+gaV9pkyR2YitHxjMwzam38ieCgqZaw+ruXlGfFKXK3ys/8xZOe10hicHtWyHCmuxO9kwY87BkeCjpbEDvtMGgB0eOAgX+AA4RZyil6eZ+8o5AOe4DtVdPAd+znA7ztH7oEdzKBKroMfXFlC3GI/acKOpDmt7alPCeisAC12/IOucQ2+gPYMZ8u1g/N6+Nl91PaK8eLpNhn6oU+rDySdDQ5Hk2nu2GSwGvESeqyLJA1OHoVvBcvVh4LlClZ8udNJU/bYwcXOPB17ScvZzXX0Y0pZrVKDu8wI9GN4a9WqMn3kFsKFoFeSp34j/A81hO27uvY+3oioEWwgotP5qxuATqErOeJDAYkCnX2Q+PeV0dNaeKG+7qcAmWJShpbHyxrp5hjHArLrKwYXJUF1RMR6++MCcF6c2D2VoahUeLeq+XasY9WrzrahzUcjRaCM8eFp3upwD+2yl0Om60IPp9Y5ghwcOYsqmx5u5uEuVmVY/VBjyvaknWHWo7qKfR1/1CgJ22gFMr2I6qaVxA8o5TToHAw6aHD03o654TsqmXpZ1zgG6nfV44D09hOtNwXpferQOnjTecPSztdq/N0V19Q+svVddVBVa24CUH6zroVsxTMR7tYcKTdVvCxM39yhr1Tmg5bQpN2vdQ+stDy4Fgq57EK6jihwoQcMwy9Dv1YFmlawKqW++j7diz0I1ORduf6URFht8AnV0GDKD69S0ZNVAYNOTz1uzqeoUeH18p3HvuYnyIRyw0NJYeWPdrEd/OvLY0rhZdE8P5iGp3JG6zxf5akll2MKt2DyUoVmPAJMYxZNVjPqebV+kztWzp/uchdQ5Xc7BQzmk9jgCu13o0ZGsi11W4XHEoWyYlw3l7F+xpJmLu1SPsl/Cik7a7+HwBNP0M0E/T4PqlSpzwOBznZTqHCK2oRxjaj+s7alNkDwbZLq/ll2WzZxDLuUhYVG7ZTB+b18H7zbPm/yJWh2N3/m9h7NOH1h7z/ZDtaHWK1K+aeowdCuYWK9+qKqo0FT9tjBxc4/V8gEt56G6+jC03jJrEZKXxg3VyQhXYzSdE0TD3t2CvFeHqg2qQuqb7+Ot2LOQOk8gzxvHxGNczRh8AoNV1T9mcJ2aVlI1gF5nZR7n7VHvDpbL21qOTr591ZDBovQvjZUZ6+bm1r6IPLY0Vmc64J8A6wuChhMfmFuxeShD02ek+wcH4tIqRv1gO8cMc1mLm41Oii7zuXIOvQyq6xZW/Zjj85YePCtf1Kezk2u4FHf5ICtssz7NNBFTHaq7dAX45z6ePL0VvCH086mrCjbPgulWBfU9ZMgvWO2HtT21CVjOdMXgpevSbOYcoI0rD1DPYPzevg7ebTbiGFb7Ye/h1BXAWlyp6mGKjmntvWo/Q7ZBapmlJ4FPXXyyYdPUYehWsBzFT522YPurr24LEzf3eOAlxSdtCurqqntovWU9A/WiYF8+dIaqMfQzSoXXkCEO2hPRqfoXj8xN9kJz/T7eij0LMYYh+6qaMfgEqhKmy6rTHySoGujUNaW5DKn/tujtY0VZgmFoG1zEolV/NQPWzXr0pyOPLY0vXZh6NvB/NfX0B+ZWbB7K0NQZcaDU/cJWMerVS7eizkWhHMInO1X/LDkHO+eQMLcWPdlfhJ0cOAi1fs3ukSu5FBfxHvo64JHFFfT4OQYOG2f62aJJUV2PnQvvsB5HHhFdfy6bZ8EjxRCfKGdFLaQLjoreOplEE52yam1PbQprXtqXxschs7263sm6Wa4JeuxP6pv7UpDznaKmHjzE8AlLICltrKKhg4dTkrUwnf7BXWimR3U6GRpsqEX3vvo3TQUNsSMJn4704DrMoFCpbyVNRrWFW6FN7e1xz0s6RwVvNqKTwleMaghrGaUps+uTRicPPytKFWI0WVejCNPUa8IndbtOR+OiF8H91kBz2I6be+/jrWDipoXUGZJP6EE5bqlD1OWTwSr6adZyyoOEcjSgCt/KDJkkf0rmtvAUYbZX1C3hpmBROu3tasawLzWH6ScyPM96ZuhxQUBDwEKMYrmvESFTXYYHRvUzYC6b0it8cEbyHmKYhyR1ejRUnXYz71QGDzOdurzEXaebc5acY/C+ih/fY3AQZWmsGHRSznvI7sj1XOorlaIXkoNfxm6c443TdF1N4ApgFk0+q8N5FnUovC28P1VnhadKLxvrUuep0s1CXXPRrwddbh/sGZpGz65f6Yuj46ir++2iU1vQRexCP52b+6qSCEjGTcTsIrxKHVXyp8Vc5CVBXRM5CB3N4C7XKdUGmQo8Gz5cbfDYVAR0mVYzTgcj/cygwc+Ml1BR54l4ls6lNiWw9pKgn0491WwNeY1iFZJMwTlWaP8IjoknWUNU6nNID9N1EMxCyTJwo7nOQgmdklSh6frQ9Hb23sfTYe6ehe5k4/KbRqtPaCKjYqvot1Vy1BcfJKZQRwPKEWYverTQIM+cAUrQUCM9zapNG1RRTzXDQzQ3n6UT8UQVdWIGPqSJG9cXJj2MLo1/OX5gcJTEbotf4eMzwns6U1akjnk+muo06TwR65dLWQWF2pG1zZJzXA8dwFDqY9rDY3JpA1wuvIRL4wpMchyTPJzhdDgg3afTMr+F4WvmkeccJFZKuitK8ZZGF8k5TodTI+k+70veicxwHPM8nOF0knOEcBceec7Bd2Vevw/lb6JEMv1+2ExyjlPwL43XvjRnOI55Hs5wIqSJPJzrH8nnYX4Lw1fOI885Ppb/UQRFsqt+ez4gOccp6G/wBGOuzqXrOsxwHPM8nOFEdFI6rKVrMua3MHzlPPKcYx7i0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqchwhhNBPco4m4tKpyHGEEEI/yTmaiEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqHtlxfPjwx6tXP7148cPSvgSX1fn5899v3/767Nl3qF26JmYeaz99+uvp02/fv/99ae9wfFgnKjFsH21PnnzDrNevf156zwUNz59/vzTCV09yjibi0ql4ZMdBbCBCXDbnuKzON29+kcIHkXPMY+2J6cLxYd0250APKRcV0gUmMl3955GcI1SSczQRl07F5Mdxxh3NlL2Qw9fW81KHy+YxxLzLRvGz93UKpB0XtPaqpopLHdbHj3+iammcBQeN95ZGCP8lOUcTcelUzHwcfK0849In3uyFnHfvfjsvGl0qjAni9wWjOJy9r1O4bM5xVVPFpQ5LG18aZ/Hq1U/JOcIeyTmaiEunYtrj4Avx8+ffn3HpE282Qw5fW58+/fa8aHSpMCYum3PcZV+ncMGc49qmiksd1h1zDrIrpifnCHsk52giLp0KH8f7978/e/YdIYHAoH8upzvX8YZ7XM0b8X/ih3q4W/3P6/Qtlon6+zel3rlMefnyRynhKyBZhfqp0ESYfgTUr4RDxSEEbRhJD5/1r/Ksq/63b39F2PJGf8i3QlulfyAphdXUAQTQibCU7BmPDHtU/wBi2rsspyKvUtFE6spFKNWSvS2LzX2xlvxPD25czzLIS4xP/cOFNcggoJOlUs3Q3ulUf81LfNZo1uOxZ+rae0jKfpqo1d/X/GhRB4ZkjyYyRf2gnqXxX6oSr0LFR2M90uyirbFxPZbMsiWw3qyO2IXpXk5TYO+Yjg0Lj4bkHE3EpVPh4+CO043PZeorm7tPN6aaCjCqcxsqSilSukJhulRpOhc9dV2gujqRZDm0UQcuXOpcwcxCHjH1o0eaBdqkyqFO2uhEm4xUDrEXcmTb0rjZKUtLCRMZZQkNDTDkJViOpo3HWvWjB22srv4KBnuP8gMaNIueahWjNB3P9rY8UDUAda3lWZtphzaik5JJm8oxhiEbj3JL0sl+tRAV751R3KXHQ45VHahXUze9J2MomO3D5ZMeewZJxKjomcES9cOwhBmUeBWa2hqjVY82vjRu0giOA0nq2pSOZm+zLCfl1MHLqQl7x/RFw8LjIDlHE3HpVPg4uON0+4MvOF277q+3MDem71PLD/csEBsUAJR/DIV+Lm7HKkCVYgkwUTLA5VsnquhS5kbW7S+84hqmeEgK60Td+1zxS7tQJ4L2ggaCBJWh2F0GO+seWbSKUa/KacqBe1uWWIV+a5BJdRcsXVc3hEb36+DWlgMr1iFZpeSMkxoeFdXpdD/yJBMKw4DMYOpQtBAy1JkrSZCF3n49dIQHB9ZmZVCiVVSHQU/dEbALmrVIeG+zw1pQlzs+pmPDwuMgOUcTcelU+Dh0pfJZw7CuXcebegsr7nJL0unYsL5nJUaFS7P2GzpZdGn8l3rzSrPqFfXbQji4oJH00HqiwkDtMXUieC7G761VGUwalh6U05SjJKbOY6oG5g6zfASbfPz4JyGTEI6MTapIYR0atoPfhi/xjCopWYNMNbXqqdBvbULekGcETx3Pqp7bqmdoVgYlwyo068TBk9Q3/cOUzc2uDa7LDcqhHtOxYeFxkJyjibh0Knwc3ODcg+QQXHbc40ojdDP6qh0uSt/4RCz9RL++Z6WTyt69KZ2bvy7Um1ea15f+uv/ggkbSQ5pIvFQT9paAOhH8JRXj2btTrj0Gk4aFBuU05cADewaqBvmzmqSepVFARoZxjgf5lqbXIQ5d3+w5dA6XOtPrKuj0V/YBZKqpe95DZrBZ3mCKmtjMEsRpbNAu1A91iYFBybDKoKfuCOrEClM2NzusBXU5Kd87pmPDwuMgOUcTcelU+Dj8+7D+Jq0YM4Siei1anlEih+7W9T3r+MQnQ3w6vdDfULQcYu4nkKheb156qLOQswTWYq7+nF9XPLigkfSQFPrvOEAYo2czBNaJwC4UZjQF45VyAZa4blilBld5yV5lelXOkLazt2XVK9U8mVTFsJYllkYBq9w/mFTBmDokq1iFOrb5K77EVNfPHqzrLdvP9A+mbnoPGWsTslCe0aHbLQgPDqzNSlUCwyqDnroj4MRp4lhtik82SGVvs8NaUJc7PqZjw8LjIDlHE3HpVPg4fAPqQtfVr3tT/dySugq5fAk81HXPUuiRjOS5OhGgSSdhSXU+qTPqoitb091J3derLn0EFNj043Mt0ow8mhUF+ZQ2KR9AEttQqEgghbIcVQzVCFFBJ4XdUWcJlnOYZJbtoSCm/orcQihiFVZXlLJCrKJOP6PasmP53pYHhn1RR4OU8+n6QF1XCyHmQG4UHRFAkoJy+5Z+xVe8gTaZR12PkAur2LFrUwdJialfdaH0V27BTuo6OPqZhVpZjmaGmP7PnBVVCWgVprhZJ7JNRu1wza1Fj9zBZmmyFgKSXC+3d0zHhoXHQXKOJuLSqfBxcFFSuPgouiKFohE3KXcuAr7cqVOhXxerhBUMiEPq56LkwtUQUNdlyhLKV9TPta4wTKn9yCOJKithIXqkWWYA8goPshxVNDdjs8InW/AS7EKm8qkYtomW0NLor5tiyMYPQxX7Sg7EfjuZKRrS3lkFq2z/5pYHhn1Va5nlSDaANskoLlKvnqnIYCSxE9uW3n+TQibiOmSkSkMsqimM1ilrU9feY1Q9LHczaXmuVKRNMggwJBfJnxZD4Gbq/zEo8SoURl1fN9UDLKGTGvywt1k9lvLJsBzsHdOxYeHRkJyjibh0Ki57HLrW67UbQghhTXKOJuLSqUjOEUII/STnaCIunYrLHsfwA3sIIYRNknM0EZdOxQWPY/h7+dIbQghhRXKOJuLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCpyHCGE0E9yjibi0qnIcYQQQj/JOZqIS6cixxFCCP0k52giLp2KHEcIIfSTnKOJuHQqchwhhNBPco4m4tKpyHGEEEI/yTmaiEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqeA4Qggh9LPcwsk5rkpcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTMe1xvH//+9On33769NfS3uHdu99evPjhzZtflvZF+fDhj1evfkL/0m5k2Bd+wBv4RM2B49EQwoQk52giLp0KHQfh7cmTb4by/Pn3xLzPn/+WZDOn5BzkBMhg6pVyDinvzznW+0rOEcIjIzlHE3HpVPg4Pn78cwhyr1//rMxDPedBILxSQiAIz9fLOYDt38vvHKR6x/u647mEEO6X5BxNxKVT8Z/nfhXkXr36iU7i+tK+PWh40DkHCce95BxwsC8yQkaXRgjhAZKco4m4dCqumnO8e/fbVRMC+Apzjs+f/37+/HtGl3YI4QGSnKOJuHQq9nIOAtvbt7/SU3/Dp1NZCOXZs+9qLvL+/e8KhPSTaqhHkioS/vjxz5cvf1QPqvSPRRiiTmhn4tOn375+/bNWr0swEQFNpOJ/53Gcc8hg/7MMlNCpPxvRSUXGsJAVAmbQQz82MIuyDNwsp20y3fYLb01bWHr/9z9skwF8olCd6y2rX4ZRhn0hhrCaMkBFttVRsK/or5aEEOYhOUcTcelUDDnHUAhdNawSJgnG9FCoUNRPeqEwSV1xV9F9CJyK8YruDDEFhdSpIIY2ZtGDjOO0dAKj9FNBhn5NhGGJAaZIA4sSqmWwLNQsNsKQLQElAZqlvEdxHWSzhlR3QiYlSin4RLnqaKMub2hdbR9h6nXLdFJBIQJYhW2ykH6t5SYopVB9PYo2rc6QxUIIU5Gco4m4dCqGnMNxi8insKe4qE6CmWOzRlVHhuCqOsKEQE1RzLNOvnPTHIqGqDh+C+lHg5ro9BJE3JoHIOYlKsMPLSpSWGM2WCHBvi4ENefAQm8flE9ImH4PoQRJ5x9oUL9M9Y6o1y1rVBkJUKHpfQ3bHOxfj7peDQ4hzENyjibi0qnYyzmEvrLrW7ghlusru8MeFTpVrxzEwgHEHNoFknQ6QgOxnABPnK7CwxIVOgedhn5mLY2Sc0hbXdRDMCyEPe5B5uCvGPoxQ79GWDl1awbtd2ncUJcbtsnEKjyMKrcj16EHI9UZQpiK5BxNxKVTcZxzAJ0Ob8ROIhnhkwwDSfdT2fw+vY6UNcpWEBuGpN8RmmyDpYmm2FD1DEtU6CTMbwZdpjNraRTDpM2LQl2LoSGx8NLI+PeMCqtLA/brdxcrp27NoP0ujRusHIZtMrEKr53g5My/OYUQpiI5RxNx6VQc5xwKZv4TAAHMQbfGSH2D118T4NPNP9KkMsRC8hKafPovCP4Fhf4agEH6FaGJmtT9U4qiuOrrcGuIuwxhvIMuYqoPMdsKtVDVVtciq6A4idGfP2SVfvhhax7V1vi092SqdgTUrRn0k5JHgaYtGbbJRJqqwzDq/I9+jqZuJ4QwCck5mohLp8LHoXDrcEXsJGYrmahhUqEUYYU94i51xUsXAnOdoh8n0IawFLpoOdaiXgMwMItORXTFVOU09KAfYQ3xydDw84PRd30X/xShfucHNJ0ZoBkjsZY6n0xBUnZqLSUWFCq2Wd5zYZYiPQLUEVYexhB7Qc96y/SwLmbIdUxHgB7vmqa3qVGmqGcYRa2NZHXngiGEeUjO0URcOhU6DqIUQWsoBDwyDGcPUAPhEOfoUXjmkyF1AsGvihGbFe9RorhIJ031KKEBLaQiA2QhymmiDWESAuoWU4wfQD86JUCF1emsm6XpuppMkc1aglk0/cMMW7P9mCH7BcZ4yMYgT5NOhFmdOqszix5JesuAgLdJnU/0ILzeplRJbD3KJ+sySo89H0KYiuQcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl04FxxFCCKGf5RZOznFV4tKpyHGEEEI/yTmaiEunIscRQgj9JOdoIi6dihxHCCH0k5yjibh0KnIcIYTQT3KOJuLSqchxhBBCP8k5mohLpyLHEUII/STnaCIunYocRwgh9JOco4m4dCqmPY73739/+vTbT5/+Wto7vHv324sXP7x588vS7uX58+9fv/55aZzL8U7pZxSZpR1CeBQk52giLp0KHQdh+8mTb4ZCQCWWf/78tySbOSXn+PDhD2QwNTlHCOFhkZyjibh0KnwcHz/+WYM3oY5oqsxDPedBsLxqQkDacY85xzUgySMFXBohhEdKco4m4tKp+M9zvwrer179RCdxfWnfHjQk57gV+mvR0gghPFKSczQRl07FVXMOwue1E4JHlnN8/Pjn06ffJucI4dGTnKOJuHQq9nKOz5//fvv2V3rq31boVBZCefbsu5qLvH//O5LqJ9VQjyRVJExMffnyR/WgSv9YhCHqBFomEnFfv/5Zq9clmOh/dELF//rhIOewWuaiCjH92ws0b/4rEJoS41P/fsJm0GQus+o/rbB+Nf2vWTVl0G/7GZJ/RN2p/ukGMiqabrWSZ3WEEUPh3f8pSQjhvkjO0URcOhVDzjEUop3SAkGIJeDRQ6FCUT+BkCio/EApBRGR+pAQEFMZVbrAEFNQSF2BFm3MogcZpqhTOoFR+qkgQ78mwrBERRrIhJQlENppokQ69a9VnLvQVCrA1lCuIZshsxnCId61huihru3QZLm1fiYyKpstSaG53il16QQLe4M05Vt6LBZCeHAk52giLp2KIedwbFPEpUepgDoJvQ72GlUdGX93R9hxkZBZdSoMD0VDVIZ/rCr9jsTo9BLE2hqVEfMSAwzVwFwlNVH6yQmoD0WSgxlqqg7U9yyp+msd8EO1alii6gTNtdoq6bMIITw4knM0EZdOxV7OIfzbwNK+4f373+mhn6IeKv6LQ2WIl4TSQb9BrAZaGCIxkBmQdugvOHuRfmBQWyU1UfpVV//AYIaaqgP1PUvW+veUDEtQrzZrrtVq+3w6AwshPESSczQRl07Fcc4BdFJU/3jzDyP4ek2GUQMnlc3v3EO8JJTWaFpBbBgaIjEhlqVfv/4ZG6qeYYmBQW2V1ETpr/WBwQw1VQfqe5YMOskSSNRImz59+ouNVKuGJapOGNSigToa6EQnTfWHEB4WyTmaiEun4jjnUMAjtqn59OYfeKquSKm6/s3B27e/qklYldgQL8lLaPKpf+UA/gWF/hpoQfoVickzqPunFCT3Iv3AoLZKaqL0Yw91duEl6Nd2qhluqg7U9yyp+kGpkhyFB2quMCxRdcKg1rmdfoLyrBDCwyI5RxNx6VT4OBTXHdL0hwzFyBoOlSUogtIkWlNX/HPhW3idoh8n0IawFLpoOdaiXgMtMItOJQGKu0oC6NHvBBrikyFnQhWpdcKkxMKSmigloOVqUWJUzXBTGcOgf7Ck6kcSmzVrzbAEW9MPGMozBrXU5QedF5/qDyE8LJJzNBGXToWOQwnEUMgPyDDqN2l9I6efsDfEQnr0gz+fDp9AVlHFiJEEVCnx132a6vHPHlpIRQbIQmUzaEOYJEa5iIp/CTAeYm6VpFn1e6LU0oOF2sJgRvXSoHCwZNBfR1Vk/3oJeuinjk6cM6iVPIXp1hBCeIgk52giLp2KHEcDZA/KtGohaViGQwhfH8k5mohLpyLH0YD+tLQ0biAL8W8/IYSvkOQcTcSlU5HjaODpzb+99b+9IOHQH4bUDCF8hSTnaCIunYocRwPvy/+iCfkH9fzbzxC+cpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Cc5RxNx6VTkOEIIoZ/kHE3EpVOR4wghhH6SczQRl05FjiOEEPpJztFEXDoVOY4QQugnOUcTcelU5DhCCKGf5BxNxKVTkeMIIYR+knM0EZdORY4jhBD6Sc7RRFw6FTmOEELoJzlHE3HpVOQ4Qgihn+QcTcSlU5HjCCGEfpJzNBGXTkWOI4QQ+knO0URcOhU5jhBC6Gc35wghhBBCuCxLnlFzjhBCCCGE65GcI4QQQggdJOcIIYQQQgfJOUIIIYRwff73v/8f+vKereRqhkcAAAAASUVORK5CYII=" /></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; * In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ** Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.</p><ul><li><strong><em>Indications for adults and children over 12 years of age (&ge; 50 kg) that require specific dosage schedules:</em></strong></li></ul><p>Acute otitis media<br />A single intramuscular dose of Ceftriaxone 1-2 g can be given.<br />Limited data suggest that in cases where the patient is severely ill or previous therapy has failed,<br />Ceftriaxone may be effective when given as an intramuscular dose of 1-2 g daily for 3 days.<br />Pre-operative prophylaxis of surgical site infections<br />2 g as a single pre-operative dose.<br />Gonorrhoea<br />500 mg as a single intramuscular dose.<br />Syphilis<br />The generally recommended doses are 500 mg-1 g once daily increased to 2 g once daily for<br />neurosyphilis for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are<br />based on limited data. National or local guidance should be taken into consideration.<br />Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])<br />2 g once daily for 14-21 days. The recommended treatment durations vary and national or local<br />guidelines should be taken into consideration.</p><p><u>&nbsp;</u></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Paediatric population</u> </em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neonates, infants and children 15 days to 12 years of age (&lt; 50</em> <em>kg)</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For children with bodyweight of 50 kg or more, the usual adult dosage should be given.</p><p><img alt="" width="500" height="328" src="data:image/png;base64,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" /></p><p>* In documented bacteraemia, the higher end of the recommended dose range should be<br />considered.<br />** Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.</p><p>&nbsp;</p><ul><li><strong>Indications for neonates, infants and children 15 days to 12 years (&lt; 50 kg) that require specific</strong><br />dosage schedules:<br />Acute otitis media<br />For initial treatment of acute otitis media, a single intramuscular dose of Ceftriaxone 50 mg/kg<br />can be given. Limited data suggest that in cases where the child is severely ill or initial therapy<br />has failed, Ceftriaxone may be effective when given as an intramuscular dose of 50 mg/kg daily<br />for 3 days.<br />Pre-operative prophylaxis of surgical site infections<br />50-80 mg/kg as a single pre-operative dose.<br />Syphilis<br />The generally recommended doses are 75-100 mg/kg (max 4 g) once daily for 10-14 days. The<br />dose recommendations in syphilis, including neurosyphilis, are based on very limited data.<br />National or local guidance should be taken into consideration.<br />Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])<br />50&ndash;80 mg/kg once daily for 14-21 days. The recommended treatment durations vary and national<br />or local guidelines should be taken into consideration.</li></ul><p>&nbsp;</p><ul><li><strong>Neonates 0-14 days</strong><br />Ceftriaxone is contraindicated in premature neonates up to a postmenstrual age of 41 weeks<br />(gestational age + chronological age).</li></ul><p><img alt="" width="500" height="308" src="data:image/png;base64,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" /></p><p>* In documented bacteraemia, the higher end of the recommended dose range should be considered.<br />A maximum daily dose of 50 mg/kg should not be exceeded.</p><p>&nbsp;</p><ul><li><strong>Indications for neonates 0-14 days that require specific dosage schedules:</strong><br />Acute otitis media<br />For initial treatment of acute otitis media, a single intramuscular dose of Ceftriaxone 50 mg/kg<br />can be given.<br />Pre-operative prophylaxis of surgical site infections<br />20-50 mg/kg as a single pre-operative dose.<br />Syphilis<br />The generally recommended dose is 50 mg/kg once daily for 10-14 days. The dose<br />recommendations in syphilis, including neurosyphilis, are based on very limited data. National or<br />local guidance should be taken into consideration.</li></ul><p><strong>Duration of therapy</strong><br />The duration of therapy varies according to the course of the disease. As with antibiotic therapy<br />in general, administration of ceftriaxone should be continued for 48 - 72 hours after the patient<br />has become afebrile or evidence of bacterial eradication has been achieved.<br /><strong>Older people</strong><br />The dosages recommended for adults require no modification in older people provided that renal<br />and hepatic function is satisfactory.<br /><strong>Patients with hepatic impairment</strong><br />Available data do not indicate the need for dose adjustment in mild or moderate liver function<br />impairment provided renal function is not impaired.<br />There are no study data in patients with severe hepatic impairment (see section 5.2).</p><p><strong>Patients with renal impairment</strong><br />In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone<br />provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine<br />clearance &lt; 10 ml/min) should the ceftriaxone dosage not exceed 2 g daily.<br />In patients undergoing dialysis no additional supplementary dosing is required following the<br />dialysis. Ceftriaxone is not removed by peritoneal- or haemodialysis. Close clinical monitoring<br />for safety and efficacy is advised.</p><p><br /><strong>Patients with severe hepatic and renal impairment</strong><br />In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety<br />and efficacy is advised.</p><p><br /><strong>Method of administration</strong><br />Intramuscular administration<br />Ceftriaxone can be administered by deep intramuscular injection. Intramuscular injections should<br />be injected well within the bulk of a relatively large muscle and not more than 1 g should be<br />injected at one site.<br />As the solvent used is lidocaine, the resulting solution should never be administered<br />intravenously (see section 4.3). The information in the Summary of Product Characteristics of<br />lidocaine should be considered.</p><p><strong>Intravenous administration</strong><br />Ceftriaxone can be administered by intravenous infusion over at least 30 minutes (preferred<br />route) or by slow intravenous injection over 5 minutes. Intravenous intermittent injection should<br />be given over 5 minutes preferably in larger veins. Intravenous doses of 50 mg/kg or more in<br />infants and children up to 12 years of age should be given by infusion. In neonates, intravenous<br />doses should be given over 60 minutes to reduce the potential risk of bilirubin encephalopathy<br />(see section 4.3 and 4.4). Intramuscular administration should be considered when the<br />intravenous route is not possible or less appropriate for the patient. For doses greater than 2 g<br />intravenous administration should be used.</p><p>Ceftriaxone is contraindicated in neonates (&le; 28 days) if they require (or are expected to require)<br />treatment with calcium-containing intravenous solutions, including continuous calcium-&nbsp;containing<br />infusions such as parenteral nutrition, because of the risk of precipitation of ceftriaxone-calcium (see section 4.3).</p><p>Diluents containing calcium, (e.g. Ringer&#39;s solution or Hartmann&#39;s solution), should not be used<br />to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for intravenous<br />administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur<br />when ceftriaxone is mixed with calcium-containing solutions in the same intravenous<br />administration line. Therefore, ceftriaxone and calcium-containing solutions must not be mixed or<br />administered simultaneously (see sections 4.3, 4.4 and 6.2).</p><p><br />For pre-operative prophylaxis of surgical site infections, ceftriaxone should be administered 30-<br />90 minutes prior to surgery.</p><p><br />For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to ceftriaxone, to any other cephalosporin or to any of the excipients listed in
section 6.1.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam
antibacterial agent (penicillins, monobactams and carbapenems).
Ceftriaxone is contraindicated in:
Premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age)*
Full-term neonates (up to 28 days of age):
- with hyperbilirubinaemia, jaundice, or who are hypoalbuminaemic or acidotic because these are
conditions in which bilirubin binding is likely to be impaired*
- if they require (or are expected to require) intravenous calcium treatment, or calcium-containing
infusions due to the risk of precipitation of a ceftriaxone-calcium salt (see sections 4.4, 4.8 and 6.2).

* In vitro studies have shown that ceftriaxone can displace bilirubin from its serum albumin
binding sites leading to a possible risk of bilirubin encephalopathy in these patients.
Contraindications to lidocaine must be excluded before intramuscular injection of ceftriaxone
when lidocaine solution is used as a solvent (see section 4.4). See information in the Summary of
Product Characteristics of lidocaine, especially contraindications.

Ceftriaxone solutions containing lidocaine should never be administered intravenously.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypersensitivity reactions</strong><br />As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity<br />reactions have been reported (see section 4.8). In case of severe hypersensitivity reactions,<br />treatment with ceftriaxone must be discontinued immediately and adequate emergency measures<br />must be initiated. Before beginning treatment, it should be established whether the patient has a<br />history of severe hypersensitivity reactions to ceftriaxone, to other cephalosporins or to any other<br />type of beta-lactam agent. Caution should be used if ceftriaxone is given to patients with a history<br />of non-severe hypersensitivity to other beta-lactam agents.<br />Severe cutaneous adverse reactions (Stevens Johnson syndrome or Lyell&#39;s syndrome/toxic<br />epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS))<br />which can be life-threatening or fatal have been reported in association of ceftriaxone treatment;<br />however, the frequency of these events is not known (see section 4.8).</p><p><br /><strong>Interaction with calcium containing products</strong><br />Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature<br />and full-term neonates aged less than 1 month have been described. At least one of them had<br />received ceftriaxone and calcium at different times and through different intravenous lines. In the<br />available scientific data, there are no reports of confirmed intravascular precipitations in patients,<br />other than neonates, treated with ceftriaxone and calcium-containing solutions or any other<br />calcium-containing products. In vitro studies demonstrated that neonates have an increased risk of<br />precipitation of ceftriaxone-calcium compared to other age groups.<br /><br />In patients of any age ceftriaxone must not be mixed or administered simultaneously with any<br />calcium-containing intravenous solutions, even via different infusion lines or at different infusion<br />sites. However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions<br />may be administered sequentially one after another if infusion lines at different sites are used or if<br />the infusion lines are replaced or thoroughly flushed between infusions with physiological saltsolution<br />to avoid precipitation. In patients requiring continuous infusion with calcium-containing<br />total parenteral nutrition (TPN) solutions, healthcare professionals may wish to consider the use<br />of alternative antibacterial treatments which do not carry a similar risk of precipitation. If the use<br />of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN solutions<br />and ceftriaxone can be administered simultaneously, albeit via different infusion lines at different<br />sites. Alternatively, infusion of TPN solution could be stopped for the period of ceftriaxone<br />infusion and the infusion lines flushed between solutions (see sections 4.3, 4.8, 5.2 and 6.2).</p><p><strong>Paediatric population</strong><br />Safety and effectiveness of Ceftriaxone in neonates, infants and children have been established<br />for the dosages described under Posology and Method of Administration (see section 4.2).<br />Studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from<br />serum albumin.<br />Ceftriaxone is contraindicated in premature and full-term neonates at risk of developing bilirubin<br />encephalopathy (see section 4.3).</p><p><br /><strong>Immune mediated haemolytic anaemia</strong><br />An immune mediated haemolytic anaemia has been observed in patients receiving cephalosporin<br />class antibacterials including Ceftriaxone (see section 4.8). Severe cases of haemolytic anaemia,<br />including fatalities, have been reported during Ceftriaxone treatment in both adults and children.<br />If a patient develops anaemia while on ceftriaxone, the diagnosis of a cephalosporin-associated<br />anaemia should be considered and ceftriaxone discontinued until the aetiology is determined.</p><p><strong>Long term treatment</strong><br />During prolonged treatment complete blood count should be performed at regular intervals.<br /><u>Colitis/Overgrowth of non-susceptible microorganisms</u><br />Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with<br />nearly all antibacterial agents, including ceftriaxone, and may range in severity from mild to lifethreatening.<br />Therefore, it is important to consider this diagnosis in patients who present with<br />diarrhoea during or subsequent to the administration of ceftriaxone (see section 4.8).<br />Discontinuation of therapy with ceftriaxone and the administration of specific treatment for<br />Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not<br />be given.<br />Superinfections with non-susceptible micro-organisms may occur as with other antibacterial<br />agents.</p><p><strong>Severe renal and hepatic insufficiency</strong><br />In severe renal and hepatic insufficiency, close clinical monitoring for safety and efficacy is<br />advised (see section 4.2).</p><p><strong>Interference with serological testing</strong><br />Interference with Coombs tests may occur, as Ceftriaxone may lead to false-positive test results.<br />Ceftriaxone can also lead to false-positive test results for galactosaemia (see section 4.8).<br />Non-enzymatic methods for the glucose determination in urine may give false-positive results.<br />Urine glucose determination during therapy with Ceftriaxone should be done enzymatically (see<br />section 4.8).<br />The presence of ceftriaxone may falsely lower estimated blood glucose values obtained with<br />some blood glucose monitoring systems. Please refer to instructions for use for each system.<br />Alternative testing methods should be used if necessary.</p><p><br /><strong>Sodium</strong><br />This medicinal product contains 82.8 mg sodium per gram, equivalent to 4.14% of the WHO<br />recommended maximum daily intake of 2 g sodium for an adult.</p><p><br /><strong>Antibacterial spectrum</strong><br />Ceftriaxone has a limited spectrum of antibacterial activity and may not be suitable for use as a<br />single agent for the treatment of some types of infections unless the pathogen has already been<br />confirmed (see section 4.2). In polymicrobial infections, where suspected pathogens include<br />organisms resistant to ceftriaxone, administration of an additional antibiotic should be considered.</p><p><strong>Use of lidocaine</strong><br />In case a lidocaine solution is used as a solvent, ceftriaxone solutions must only be used for<br />intramuscular injection. Contraindications to lidocaine, warnings and other relevant information<br />as detailed in the Summary of Product Characteristics of lidocaine must be considered before use<br />(see section 4.3). The lidocaine solution should never be administered intravenously.</p><p><strong>Biliary lithiasis</strong><br />When shadows are observed on sonograms, consideration should be given to the possibility of<br />precipitates of calcium ceftriaxone. Shadows, which have been mistaken for gallstones, have been<br />detected on sonograms of the gallbladder and have been observed more frequently at ceftriaxone<br />doses of 1 g per day and above. Caution should be particularly considered in the paediatric<br />population. Such precipitates disappear after discontinuation of ceftriaxone therapy. Rarely<br />precipitates of calcium ceftriaxone have been associated with symptoms. In symptomatic cases,<br />conservative nonsurgical management is recommended and discontinuation of ceftriaxone<br />treatment should be considered by the physician based on specific benefit risk assessment (see<br />section 4.8).</p><p><strong>Biliary stasis</strong><br />Cases of pancreatitis, possibly of biliary obstruction aetiology, have been reported in patients<br />treated with Ceftriaxone (see section 4.8). Most patients presented with risk factors for biliary<br />stasis and biliary sludge e.g. preceding major therapy, severe illness and total parenteral nutrition.<br />A trigger or cofactor of Ceftriaxone-related biliary precipitation cannot be ruled out.</p><p><br /><strong>Renal lithiasis</strong><br />Cases of renal lithiasis have been reported, which is reversible upon discontinuation of<br />ceftriaxone (see section 4.8). In symptomatic cases, sonography should be performed. Use in<br />patients with history of renal lithiasis or with hypercalciuria should be considered by the<br />physician based on specific benefit risk assessment.</p><p><br /><strong>Jarisch-Herxheimer reaction (JHR)</strong><br />Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction (JHR)<br />shortly after ceftriaxone treatment is started. JHR is usually a self - limiting condition or can be<br />managed by symptomatic treatment. The antibiotic treatment should not be discontinued if such<br />reaction occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Calcium-containing diluents, such as Ringer&#39;s solution or Hartmann&#39;s solution, should not be used<br />to reconstitute Ceftriaxone vials or to further dilute a reconstituted vial for intravenous<br />administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur<br />when ceftriaxone is mixed with calcium-containing solutions in the same intravenous<br />administration line. Ceftriaxone must not be administered simultaneously with calciumcontaining<br />intravenous solutions, including continuous calcium-containing infusions such as<br />parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and<br />calcium-containing solutions may be administered sequentially of one another if the infusion<br />lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using<br />adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an<br />increased risk of precipitation of ceftriaxone-calcium (see sections 4.2, 4.3, 4.4, 4.8 and 6.2).<br />Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of<br />bleeding. It is recommended that the International Normalised Ratio (INR) is monitored<br />frequently and the posology of the anti-vitamin K drug adjusted accordingly, both during and<br />after treatment with ceftriaxone (see section 4.8).</p><p><br />There is conflicting evidence regarding a potential increase in renal toxicity of aminoglycosides<br />when used with cephalosporins. The recommended monitoring of aminoglycoside levels (and<br />renal function) in clinical practice should be closely adhered to in such cases.<br />In an in-vitro study antagonistic effects have been observed with the combination of<br />chloramphenicol and ceftriaxone. The clinical relevance of this finding is unknown.<br />There have been no reports of an interaction between ceftriaxone and oral calcium-containing<br />products or interaction between intramuscular ceftriaxone and calcium-containing products<br />(intravenous or oral).</p><p><br />In patients treated with ceftriaxone, the Coombs&#39; test may lead to false-positive test results.<br />Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia.<br />Likewise, non-enzymatic methods for glucose determination in urine may yield false-positive<br />results. For this reason, glucose level determination in urine during therapy with ceftriaxone<br />should be carried out enzymatically.</p><p><br />No impairment of renal function has been observed after concurrent administration of large doses<br />of ceftriaxone and potent diuretics (e.g. furosemide).</p><p><br />Simultaneous administration of probenecid does not reduce the elimination of ceftriaxone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />Ceftriaxone crosses the placental barrier. There are limited amounts of data from the use of<br />ceftriaxone in pregnant women. Animal studies do not indicate direct or indirect harmful effects<br />with respect to embryonal/foetal, perinatal and postnatal development (see section 5.3).<br />Ceftriaxone should only be administered during pregnancy and in particular in the first trimester<br />of pregnancy if the benefit outweighs the risk.</p><p><br /><strong>Breastfeeding</strong><br />Ceftriaxone is excreted into human milk in low concentrations but at therapeutic doses of<br />ceftriaxone no effects on the breastfed infants are anticipated. However, a risk of diarrhoea and<br />fungal infection of the mucous membranes cannot be excluded. The possibility of sensitisation<br />should be taken into account. A decision must be made whether to discontinue breast-feeding or<br />to discontinue/abstain from ceftriaxone therapy, taking into account the benefit of breast feeding<br />for the child and the benefit of therapy for the woman.</p><p><br /><strong>Fertility</strong><br />Reproductive studies have shown no evidence of adverse effects on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During treatment with ceftriaxone, undesirable effects may occur (e.g. dizziness), which may<br />influence the ability to drive and use machines (see section 4.8). Patients should be cautious when<br />driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia,<br />thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.<br />Data to determine the frequency of ceftriaxone ADRs was derived from clinical trials.<br />The following convention has been used for the classification of frequency:<br />Very common (&ge; 1/10)<br />Common (&ge; 1/100 - &lt; 1/10)<br />Uncommon (&ge; 1/1000 - &lt; 1/100)<br />Rare (&ge; 1/10000 - &lt; 1/1000)<br />Not known (cannot be estimated from the available data)</p><p><img alt="" width="500" height="965" src="data:image/png;base64,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" /></p><p>a Based on post-marketing reports. Since these reactions are reported voluntarily from a<br />population of uncertain size, it is not possible to reliably estimate their frequency which is<br />therefore categorised as not known.<br />b See section 4.4<br /><em>Description of selected adverse reactions</em></p><p><u>Infections and infestations</u><br />Reports of diarrhoea following the use of ceftriaxone may be associated with Clostridium<br />difficile. Appropriate fluid and electrolyte management should be instituted (see section 4.4).<br /><u>Ceftriaxone-calcium salt precipitation</u><br />Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and<br />full-term neonates (aged &lt; 28 days) who had been treated with intravenous ceftriaxone and<br />calcium. Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys postmortem.<br />The high risk of precipitation in neonates is a result of their low blood volume and the<br />longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).<br />Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children<br />treated with high doses (e.g. &ge; 80 mg/kg/day or total doses exceeding 10 grams) and who have<br />other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or<br />symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually<br />reversible upon discontinuation of ceftriaxone (see section 4.4).<br />Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in<br />patients treated with doses higher than the recommended standard dose. In children, prospective<br />studies have shown a variable incidence of precipitation with intravenous application - above 30<br />% in some studies. The incidence appears to be lower with slow infusion (20 - 30 minutes). This<br />effect is usually asymptomatic, but the precipitations have been accompanied by clinical<br />symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is<br />recommended in these cases. Precipitation is usually reversible upon discontinuation of<br />ceftriaxone (see section 4.4).</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In overdose, the symptoms of nausea, vomiting and diarrhoea can occur. Ceftriaxone<br />concentrations cannot be reduced by haemodialysis or peritoneal dialysis. There is no specific<br />antidote. Treatment of overdose should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Third-generation cephalosporins.<br />ATC code: J01DD04.<br /><strong><u>Mode of action</u></strong><br />Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding<br />proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which<br />leads to bacterial cell lysis and death.<br /><strong><u>Resistance</u></strong><br />Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms:<br />&bull; hydrolysis by beta-lactamases, including extended-spectrum beta-lactamases (ESBLs),<br />carbapenemases and Amp C enzymes that may be induced or stably derepressed in certain<br />aerobic Gram-negative bacterial species.<br />&bull; reduced affinity of penicillin-binding proteins for ceftriaxone.<br />&bull; outer membrane impermeability in Gram-negative organisms.<br />&bull; bacterial efflux pumps.<br /><strong><u>Susceptibility testing breakpoints</u></strong><br />Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on<br />Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><p><img alt="" width="500" height="373" src="data:image/png;base64,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" /></p><p>a. Susceptibility inferred from cefoxitin susceptibility.<br />b. Susceptibility inferred from penicillin susceptibility.<br />c. Isolates with a ceftriaxone MIC above the susceptible breakpoint are rare and, if found, should<br />be re-tested and, if confirmed, should be sent to a reference laboratory.<br />d. Breakpoints apply to a daily intravenous dose of 1 g x 1 and a high dose of at least 2 g x 1.</p><p><strong><u>Clinical efficacy against specific pathogens</u></strong><br />The prevalence of acquired resistance may vary geographically and with time for selected species<br />and local information on resistance is desirable, particularly when treating severe infections. As<br />necessary, expert advice should be sought when the local prevalence of resistance is such that the<br />utility of ceftriaxone in at least some types of infections is questionable.</p><p><u>Commonly susceptible species</u><br />Gram-positive aerobes<br />Staphylococcus aureus (methicillin-susceptible)&pound;<br />Staphylococci coagulase-negative (methicillin-susceptible)&pound;<br />Streptococcus pyogenes (Group A)<br />Streptococcus agalactiae (Group B)<br />Streptococcus pneumoniae<br />Viridans Group Streptococci</p><p><u>Gram-negative aerobes</u><br />Borrelia burgdorferi<br />Haemophilus influenzae<br />Haemophilus parainfluenzae<br />Moraxella catarrhalis<br />Neisseria gonorrhoea<br />Neisseria meningitidis<br />Proteus mirabilis<br />Providencia spp.<br />Treponema pallidum</p><p><strong>Species for which acquired resistance may be a problem</strong></p><p><u>Gram-positive aerobes</u><br />Staphylococcus epidermidis+<br />Staphylococcus haemolyticus+<br />Staphylococcus hominis+<br /><u>Gram-negative aerobes</u><br />Citrobacter freundii<br />Enterobacter aerogenes<br />Enterobacter cloacae<br />Escherichia coli%<br />Klebsiella pneumoniae%<br />Klebsiella oxytoca%<br />Morganella morganii<br />Proteus vulgaris<br />Serratia marcescens<br /><u>Anaerobes</u><br />Bacteroides spp.<br />Fusobacterium spp.<br />Peptostreptococcus spp.<br />Clostridium perfringens</p><p><strong>Inherently resistant organisms</strong></p><p><u>Gram-positive aerobes</u><br />Enterococcus spp.<br />Listeria monocytogenes<br /><u>Gram-negative aerobes</u><br />Acinetobacter baumannii<br />Pseudomonas aeruginosa<br />Stenotrophomonas maltophilia<br /><u>Anaerobes</u><br />Clostridium difficile<br />Others:<br />Chlamydia spp.<br />Chlamydophila spp.<br />Mycoplasma spp.<br />Legionella spp.<br />Ureaplasma urealyticum</p><p>&pound; All methicillin-resistant staphylococci are resistant to ceftriaxone.<br />+ Resistance rates &gt;50% in at least one region<br />% ESBL producing strains are always resistant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><br /><u>Intramuscular administration</u><br />Following intramuscular injection, mean peak plasma ceftriaxone levels are approximately half<br />those observed after intravenous administration of an equivalent dose. The maximum plasma<br />concentration after a single intramuscular dose of 1 g is about 81 mg/l and is reached in 2 - 3<br />hours after administration.<br />The area under the plasma concentration-time curve after intramuscular administration is<br />equivalent to that after intravenous administration of an equivalent dose.<br /><u>Intravenous administration</u><br />After intravenous bolus administration of ceftriaxone 500 mg and 1 g, mean peak plasma<br />ceftriaxone levels are approximately 120 and 200 mg/l respectively. After intravenous infusion of<br />ceftriaxone 500 mg, 1 g and 2 g, the plasma ceftriaxone levels are approximately 80, 150 and 250 mg/l respectively.</p><p><strong>Distribution</strong><br />The volume of distribution of ceftriaxone is 7 &ndash; 12 l. Concentrations well above the minimal<br />inhibitory concentrations of most relevant pathogens are detectable in tissue including lung, heart,<br />biliary tract/liver, tonsil, middle ear and nasal mucosa, bone, and in cerebrospinal, pleural,<br />prostatic and synovial fluids. An 8 - 15 % increase in mean peak plasma concentration (Cmax) is<br />seen on repeated administration; steady state is reached in most cases within 48 - 72 hours<br />depending on the route of administration.</p><p><strong>Penetration into particular tissues</strong><br />Ceftriaxone penetrates the meninges. Penetration is greatest when the meninges are inflamed.<br />Mean peak ceftriaxone concentrations in CSF in patients with bacterial meningitis are reported to<br />be up to 25 % of plasma levels compared to 2 % of plasma levels in patients with uninflamed<br />meninges. Peak ceftriaxone concentrations in CSF are reached approximately 4-6 hours after<br />intravenous injection. Ceftriaxone crosses the placental barrier and is excreted in the breast milk<br />at low concentrations (see section 4.6).<br /><strong>Protein binding</strong><br />Ceftriaxone is reversibly bound to albumin. Plasma protein binding is about 95 % at plasma<br />concentrations below 100 mg/l. Binding is saturable and the bound portion decreases with rising<br />concentration (up to 85 % at a plasma concentration of 300 mg/l).<br /><strong>Biotransformation</strong><br />Ceftriaxone is not metabolised systemically; but is converted to inactive metabolites by the gut<br />flora.</p><p><strong>Elimination</strong><br />Plasma clearance of total ceftriaxone (bound and unbound) is 10 - 22 ml/min. Renal clearance is<br />5 - 12 ml/min. 50 - 60 % of ceftriaxone is excreted unchanged in the urine, primarily by<br />glomerular filtration, while 40 - 50 % is excreted unchanged in the bile. The elimination half-life<br />of total ceftriaxone in adults is about 8 hours.<br /><br /><strong>Patients with renal or hepatic impairment</strong><br />In patients with renal or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only<br />minimally altered with the half-life slightly increased (less than two fold), even in patients with<br />severely impaired renal function.<br />The relatively modest increase in half-life in renal impairment is explained by a compensatory<br />increase in non-renal clearance, resulting from a decrease in protein binding and corresponding<br />increase in non-renal clearance of total ceftriaxone.<br />In patients with hepatic impairment, the elimination half-life of ceftriaxone is not increased, due<br />to a compensatory increase in renal clearance. This is also due to an increase in plasma free<br />fraction of ceftriaxone contributing to the observed paradoxical increase in total drug clearance,<br />with an increase in volume of distribution paralleling that of total clearance.<br /><strong>Older people</strong><br />In older people aged over 75 years the average elimination half-life is usually two to three times<br />that of young adults.</p><p><strong>Paediatric population</strong><br />The half-life of ceftriaxone is prolonged in neonates. From birth to 14 days of age, the levels of<br />free ceftriaxone may be further increased by factors such as reduced glomerular filtration and<br />altered protein binding. During childhood, the half-life is lower than in neonates or adults.<br />The plasma clearance and volume of distribution of total ceftriaxone are greater in neonates,<br />infants and children than in adults.<br /><strong>Linearity/non-linearity</strong><br />The pharmacokinetics of ceftriaxone are non-linear and all basic pharmacokinetic parameters,<br />except the elimination half-life, are dose dependent if based on total drug concentrations,<br />increasing less than proportionally with dose. Non-linearity is due to saturation of plasma protein<br />binding and is therefore observed for total plasma ceftriaxone but not for free (unbound)<br />ceftriaxone.</p><p><strong>Pharmacokinetic/pharmacodynamic relationship</strong><br />As with other beta-lactams, the pharmacokinetic-pharmacodynamic index demonstrating the best<br />correlation with in vivo efficacy is the percentage of the dosing interval that the unbound<br />concentration remains above the minimum inhibitory concentration (MIC) of ceftriaxone for<br />individual target species (i.e. %T &gt; MIC).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is evidence from animal studies that high doses of ceftriaxone calcium salt led to formation<br />of concrements and precipitates in the gallbladder of dogs and monkeys, which proved to be<br />reversible. Animal studies produced no evidence of toxicity to reproduction and genotoxicity.<br />Carcinogenicity studies on ceftriaxone were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin,<br />fluconazole, aminoglycosides and labetalol.<br />Solutions containing ceftriaxone should not be mixed with or added to other agents except those<br />mentioned in section 6.6. In particular diluents containing calcium, (e.g. Ringer&#39;s solution,<br />Hartmann&#39;s solution) should not be used to reconstitute ceftriaxone vials or bottles or to further<br />dilute a reconstituted vial or bottle for intravenous administration because a precipitate can form.<br />Ceftriaxone must not be mixed or administered simultaneously with calcium containing solutions<br />including total parenteral nutrition (see section 4.2, 4.3, 4.4 and 4.8).<br />If treatment with a combination of another antibiotic with Ceftriaxone is intended, administration<br />should not occur in the same syringe or in the same infusion solution.<br />This medicinal product must not be mixed with other medicinal products except those mentioned<br />in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
Chemical and physical in-use stability of the reconstituted product has been demonstrated for at
least 6 hours at or below 25°C or 24 hours at 2-8°C.
From a microbiological point of view, the product should be used immediately. If not used
immediately, in-use storage times and conditions prior to use are the responsibility of the user and
would not be longer than 24 hours at 2 to 8°C, unless reconstitution/dilution has taken place in
controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30oC.<br />Keep the vial in the outer carton in order to protect from light.<br />For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftriaxone 1 g Powder for Solution for Injection or Infusion<br />20 ml moulded (Type II) clear glass vial; stoppered with 20 mm grey bromo butyl rubber<br />stopper and sealed with 20 mm aluminium flip-off seal containing<br />Ceftriaxone Sodium equivalent to Ceftriaxone 1 g<br />The medicinal product is supplied in pack sizes of 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concentrations for the intravenous injection: 100 mg/ml,<br />Concentrations for the intravenous infusion: 50 mg/ml<br />(Please refer to section 4.2 for further information).</p><p><strong>Preparation of solutions for injection and infusion</strong><br />The use of freshly prepared solutions is recommended. For storage conditions of the reconstituted<br />medicinal product, see section 6.3.<br />Ceftriaxone should not be mixed in the same syringe with any drug other than 1% Lidocaine<br />Hydrochloride solution (for intramuscular injection only).<br />The infusion line should be flushed after each administration.</p><p><br /><strong>Ceftriaxone 1 g Powder for Solution for Injection or Infusion</strong><br />For IV injection 1 g Ceftriaxone is dissolved in 10 ml of water for injections; which produces a<br />clear solution. The injection should be administered over 5 minutes, directly into the vein or<br />via the tubing of an intravenous infusion.</p><p><br />For IM injection 1 g Ceftriaxone is dissolved in 3.5 ml of 1% Lidocaine Hydrochloride<br />solution; which produces a clear solution. The solution should be administered by deep<br />intramuscular injection. Dosages greater than 1 g should be divided and injected at more than one<br />site.</p><p><br />The displacement volume of 1 g of Ceftriaxone is 0.71 ml in water for injections and 1%<br />lidocaine hydrochloride solution. When adding 10 ml of water for injections, the final<br />concentration of the reconstituted solution is 93.37 mg/ml. When adding 3.5 ml of 1% lidocaine<br />hydrochloride solution, the final concentration of the reconstituted solution is 237.53 mg/ml.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Venus Remedies Limited
Hill Top Industrial Estate, Jharmajiri EPIP, Phase - I (Extn.)
Bhatoli Kalan, Baddi, Distt. Solan (Himachal Pradesh), 173205. India
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XXXX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>